Post-Cardiac Arrest Care

Therapeutic Hypothermia, Patient Outcomes and Relatives’ Experiences

ING-MARIE LARSSON
Dissertation presented at Uppsala University to be publicly examined in Enghoffsalen, ingång 50 bv., Akademiska sjukhuset, Uppsala, Friday, 10 October 2014 at 13:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in Swedish. Faculty examiner: Professor Jo Kramer-Johansen (Department of Acute Medicine, University of Oslo).

Abstract

The overall aim of the thesis was to study post-resuscitation care of cardiac arrest (CA) patients with a focus on therapeutic hypothermia treatment, outcomes up to six months post-CA and relatives’ experiences during the hospital stay.

In Paper I, the aim was to assess effectiveness of hypothermia treatment with cold, 4°C, intravenous crystalloid infusion combined with ice packs. In conclusion, the described cooling method was found to be useful for inducing and maintaining hypothermia, allowed good temperature control during rewarming and to be feasible in clinical practice.

The aim in Paper II was to investigate biomarkers and the association of serum glial fibrillary acidic protein (GFAP) levels with outcome, and to compare GFAP with neuron-specific enolase (NSE) and S100B. The result showed increased GFAP levels in the poor outcome group, but did not show sufficient sensitivity to predict neurological outcome. Both NSE and S100B were shown to be better predictors. A combination of the investigated biomarkers did not increase the ability to predict neurological outcome.

In Paper III, the aim was to investigate whether there were any changes in and correlations between anxiety, depression and health-related quality of life (HRQoL) over time, between hospital discharge and one and six months post-CA. There was improvement over time in HRQoL, but changes over time in anxiety and depression were not found. Physical problems seemed to affect HRQoL more than psychological problems. The results also indicate that the less anxiety and depression patients perceive, the better their HRQoL.

In the fourth paper, the aim was to describe relatives’ experiences during the next of kin’s hospital stay after surviving a CA. The analysis resulted in three themes: The first period of chaos, Feeling secure in a difficult situation, and Living in a changed existence.

In conclusion, the results of the thesis have helped to improve knowledge within the areas studied and reveal aspects that should be taken into account in the overall treatment of this group of patients. The thesis have also shown the importance of developing an overall view and establishing a chain of care from an individual’s CA until follow-up for both the patient and his/her relatives.

Keywords: cardiac arrest, therapeutic hypothermia, prognostication, outcome, quality of life, relatives

Ing-Marie Larsson, Department of Surgical Sciences, Akademiska sjukhuset, Uppsala University, SE-75185 Uppsala, Sweden.

© Ing-Marie Larsson 2014

ISSN 1651-6206
ISBN 978-91-554-9009-6
urn:nbn:se:uu:diva-229758 (http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-229758)
To my family
This thesis is based on the following papers, which are referred to in the text by their Roman numerals.


Reprints were made with permission from the respective publishers.
Contents

Introduction ..............................................................................................................................11

Background .............................................................................................................................13
   Surviving cardiac arrest ......................................................................................................13
   Post resuscitation care ........................................................................................................13
   Brain injury after cardiac arrest ........................................................................................14
   Therapeutic hypothermia .....................................................................................................15
   Neuroprotective mechanisms ..............................................................................................15
   Applications of therapeutic hypothermia after cardiac arrest ............................................16

Prognostication .......................................................................................................................18
   The natural course of recovery after hypoxic brain injury ................................................18
   Prediction of neurological outcome ....................................................................................19
   Biomarkers ..........................................................................................................................20
   Withdrawal of care ................................................................................................................21

Outcome after cardiac arrest .................................................................................................21
   Neurological outcome .........................................................................................................22
   Health-related quality of life ...............................................................................................22
   Anxiety and depression .........................................................................................................23

Relatives ..................................................................................................................................23
   Relatives of critically ill persons ..........................................................................................23
   Relatives of cardiac arrest patients ....................................................................................24

Rationale for the thesis ...........................................................................................................24

Aims ........................................................................................................................................26

Materials and methods .........................................................................................................27

Paper I .....................................................................................................................................28
   Settings and participants .....................................................................................................28
   Cooling method ...................................................................................................................29
   Treatment protocol ..............................................................................................................29
   Data collection and monitoring ..........................................................................................29
   Statistical analysis ................................................................................................................30

Paper II ....................................................................................................................................30
   Settings and participants .....................................................................................................30
   Data collection ......................................................................................................................30
   Analysis of biomarkers ........................................................................................................31
   Statistical analysis ...............................................................................................................31
Results ........................................................................................................37

Paper I ...........................................................................................................37
  Temperature control ................................................................................37
  Outcome .....................................................................................................38

Paper II .........................................................................................................39
  GFAP ..........................................................................................................40
  NSE ............................................................................................................40
  S100B .........................................................................................................40
  Comparisons of biomarkers ....................................................................41

Paper III ........................................................................................................42
  Outcome .....................................................................................................42
  Changes over time in anxiety, depression and HRQoL .........................43
  Correlation between anxiety and depression and HRQoL ....................44
  Descriptive distributions of the questionnaires .........................................46

Paper IV ........................................................................................................47
  The first period of chaos ...........................................................................47
  Feeling secure in a difficult situation .......................................................47
  Living in a changed existence ..................................................................48

Discussion ..................................................................................................49
  Therapeutic hypothermia .........................................................................49
  Prognostication ........................................................................................49
  Outcome ....................................................................................................51
  Relative’s experiences ..............................................................................55
  Methodological considerations ..............................................................56

Conclusions ...............................................................................................60

Clinical implications and future perspectives .........................................61

Svensk sammanfattning (Swedish summary) .............................................63

Acknowledgements ....................................................................................65

References ..................................................................................................67
**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC</td>
<td>Area Under the Curve</td>
</tr>
<tr>
<td>CA</td>
<td>Cardiac Arrest</td>
</tr>
<tr>
<td>CBF</td>
<td>Cerebral Blood Flow</td>
</tr>
<tr>
<td>CPC</td>
<td>Cerebral Performance Categories</td>
</tr>
<tr>
<td>CPR</td>
<td>Cardiopulmonary Resuscitation</td>
</tr>
<tr>
<td>CT</td>
<td>Computed Tomography</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalogram</td>
</tr>
<tr>
<td>EQ5D</td>
<td>Euroqol</td>
</tr>
<tr>
<td>EQ-VAS</td>
<td>Euroqol Visual Analogue Scale</td>
</tr>
<tr>
<td>FPR</td>
<td>False Positive Rate</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow Coma Scale</td>
</tr>
<tr>
<td>GFAP</td>
<td>Glial Fibrillary Acidic Protein</td>
</tr>
<tr>
<td>HADS</td>
<td>Hospital Anxiety and Depression Scale</td>
</tr>
<tr>
<td>HRQoL</td>
<td>Health-related Quality of Life</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>M1</td>
<td>Measurement Occasion 1</td>
</tr>
<tr>
<td>M2</td>
<td>Measurement Occasion 2</td>
</tr>
<tr>
<td>M3</td>
<td>Measurement Occasion 3</td>
</tr>
<tr>
<td>MCS</td>
<td>Mental Component Score</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic Resonance Imaging</td>
</tr>
<tr>
<td>mRS</td>
<td>Modified Rankin Scale</td>
</tr>
<tr>
<td>NSE</td>
<td>Neuron-Specific Enolase</td>
</tr>
<tr>
<td>OHCA</td>
<td>Out of Hospital Cardiac Arrest</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous Coronary Intervention</td>
</tr>
<tr>
<td>PCS</td>
<td>Physical Component Score</td>
</tr>
<tr>
<td>PEA</td>
<td>Pulseless Electric Activity</td>
</tr>
<tr>
<td>PTSD</td>
<td>Post Traumatic Stress Disorder</td>
</tr>
<tr>
<td>QoL</td>
<td>Quality of Life</td>
</tr>
<tr>
<td>RLS</td>
<td>Reaction Level Scale</td>
</tr>
<tr>
<td>ROC</td>
<td>Receiver Operating Characteristic</td>
</tr>
<tr>
<td>ROSC</td>
<td>Return of Spontaneous Circulation</td>
</tr>
<tr>
<td>SF12</td>
<td>Short form 12</td>
</tr>
<tr>
<td>SSEP</td>
<td>Somatosensory Evoked Potentials</td>
</tr>
<tr>
<td>TH</td>
<td>Therapeutic Hypothermia</td>
</tr>
<tr>
<td>VF</td>
<td>Ventricular Fibrillation</td>
</tr>
</tbody>
</table>
VT Ventricular Tachycardia
Introduction

Cardiac arrest (CA) is usually an unexpected event and extremely stressful for the people nearby, who are often relatives. It is a life-threatening condition, and the survival rate is low. In Sweden in 2012, the survival rate one month after a CA – which occurred out of hospital and was treated by ambulance personnel – was 10.3%.¹ In Europe, approximately 275,000 CA cases are treated annually by the emergency medical service, and of those, about 10% are expected to survive until hospital discharge,² but there is great variation in the reported survival rate.³ Survivors are treated in an intensive care unit (ICU), and the prognosis is uncertain not only due to the heart disease, but mostly with regard to neurological symptoms and the sequelae of the asphyxia during the CA. For the relatives, it is a time characterized by being torn between hope and despair.

In my profession as an intensive care nurse, I meet CA patients and their relatives. In the ICU, we treat the patients with life support to try to ensure survival with the best possible outcome. Due to the serious disease in addition affected by asphyxia, there are questions concerning the patient's prognosis and ability to return to a life of dignity. When caring for these patients we are facing relatives who have questions and need support to encounter this situation.

One CA patient is a man, 68 years old. He had his CA at home and his wife started cardiopulmonary resuscitation (CPR). He arrived at hospital unconscious and therapeutic hypothermia (TH) was initiated at the emergency ward. At the ICU, three days after the CA, he had reached normal temperature and started to wake up. He could not talk and was motor agitated. The next day he was moved to the medical ward. He began to talk, but asked the same question over and over again, forgetting the answer immediately. He was still motor agitated and had sleeping problems. Day by day he got better and 12 days after the CA, he was discharged from hospital. He had no memory from the event but thought he felt quite all right and was looking forward to going home. His wife was worried, she did not think he looks the same and she did not know what will happen.

Another CA patient is a 75-years old woman who easy reached the target temperature for hypothermia but took long time to rewarm, sedation had been removed but she was still unconscious. She initiated spontaneous
breathing through the ventilator, coughed and had opened her eyes, but has made no contact. Her relatives were worried but hopeful.

This thesis will focus on CA patients who reach the ICU and the chain of care for patients and their relatives. It covers a method of therapeutic hypothermia, prognostication with biomarkers, patients’ outcomes of health-related quality of life (HRQoL), anxiety and depression until six months post-CA as well as relatives’ experiences during the first six weeks after the next of kin’s CA.
Background

Surviving cardiac arrest

In 1991, the first Utstein guidelines were presented to help medical professionals report CA in a uniform manner. The Utstein templates have been revised, and been used in published studies and registries, thus enabling comparisons of findings. This has resulted in improved knowledge about CA, CPR and patient outcomes, knowledge that has come to form the foundation of international consensus and resuscitation guidelines.

To survive a CA with a good outcome, there are many pieces that must fall into place. The chain of survival (Figure 1) illustrates the interventions that need to work in order to optimize the survival with a good outcome after a CA.

![Chain of survival](image)

*Figure 1. The European Resuscitation Council’s; Chain of survival.*

Post resuscitation care

After resuscitation and return of spontaneous circulation (ROSC), the post-CA care plays an important role in increasing survival and reducing morbidity. After ROSC, a phase of pathophysiological processes called post-
cardiac arrest syndrome occurs. The syndrome includes brain injury, myocardial dysfunction, systemic ischemia/reperfusion response, the process that caused the CA and the patient’s co-morbidities. The syndrome is complex and patients have sepsis-like symptoms. 

In the immediate and early phase after ROSC, care of the patient is resource-intensive and a multidisciplinary team of healthcare providers is needed. To enhance the quality of care, treatment protocols have been shown to improve post-CA care and patient outcomes. Post-resuscitation care should follow guidelines for severely ill patients. Treatment of circulation should include hemodynamic stabilization and optimization. Adequate circulation is necessary for the brain and the myocardium. Hemodynamic instability, hypotension and arrhythmias need to be treated, but the optimal mean arterial pressure is not known. Coronary artery disease is common in CA patients, and early diagnosis and treatment with angiography and percutaneous coronary intervention (PCI) are recommended. Ventilation and oxygenation need to be optimized. Controlled mechanical ventilation should be initiated as early as possible to achieve normoventilation and avoid hypoxia. Hyperoxia and hyperventilation should also be avoided as they may worsen brain injury. Metabolic controls are necessary, including blood glucose, electrolytes, lactate and acid-base and normal values are pursued. Post-CA care should also include TH for protection of the brain. Fever post-CA have been shown to be associated with unfavorable outcome and should be avoided, also after completing TH.

Brain injury after cardiac arrest

The brain is particularly vulnerable to hypoxic ischemia due to its limited tolerance and its sensitivity to reperfusion. In animal models, cerebral ischemia for more than 5 minutes showed necrotic neurons to such a degree that irreversible damage occurred and after 15 minutes of global ischemia, 95% of the brain tissue was damaged. Interruption of circulation leads to biochemical changes. The event includes reduction of ATP production, changes in the intra- and extracellular electrolyte composition, which include disrupted calcium homeostasis, acidosis, releases of glutamate and free radicals and increased production of nitric oxide. Also functional changes of the cell with mitochondrial damage are seen. All this leads to cell damage. During reperfusion the toxic damage is ongoing, triggered by a second cascade of the events. Iceemic cell damage and death is often delayed, and the delay varies between a few hours to several days after ROSC, the process is complex and there is an interaction between different changes. The cerebral perfusion and cerebral blood flow (CBF) are affected after CA and ROSC. During the first minutes after ROSC, the CBF is increased. After the hyperaemic period, there are a period followed by hypoperfusion, which lasts for 6-24 hours after the CA and before normal CBF is achieved.
Cerebral autoregulation is affected\textsuperscript{,25} which may affect the risk of cerebral damage. A secondary, delayed window of cerebral metabolic changes begins, lasting for several days.\textsuperscript{26}

**Therapeutic hypothermia**

Hypothermia is a body temperature below normal (35°C) and TH is defined as a controlled lowering of the body temperature.\textsuperscript{27} TH has been used for patients undergoing intracerebral aneurysm and cardiac surgery since 1950s. During the 1950s and 1960s deep TH (below 30°C) was used in clinical trials and resulted in a large number of side effects.\textsuperscript{27} Clinical use of TH after CA was first presented in 1958.\textsuperscript{28} In 1990, it was reported that mild hypothermia (34°C) after CA improved neurological outcomes in dogs.\textsuperscript{29} In 2002, two randomized and controlled studies revealed improved neurological outcomes\textsuperscript{30, 31} and survival\textsuperscript{31} after CA in patients treated with TH 32-34°C. In 2013, a randomized and controlled study, compared TH at 33°C and 36°C and found no differences in outcome.\textsuperscript{16}

**Neuroprotective mechanisms**

TH affects the cerebral damaging mechanisms along different pathways at the same time and decreases cell death, apoptosis and brain infarct volume.\textsuperscript{32} Cerebral metabolism is temperature dependent and decreases with lowered temperature. Cerebral metabolism is reduced by between 5 and 7% per decreased degree body temperature.\textsuperscript{27} TH protection of the brain is greater than can be explained by decrease in metabolism, therefore other mechanisms also result in neuroprotection.\textsuperscript{33} In a non-injured brain, CBF decreases with lowered body temperature and there is also a relation between metabolism and CBF. However, the data on CBF and hypothermia after hypoxic brain injury have been conflicting.\textsuperscript{33}

Hypothermia’s non-metabolic effects include reduction of glutamate release, intracellular acidosis and free radical production. Hypothermia also includes a reduction of the inflammatory processes with reduction of cytokine production and leucocyte infiltration. It also suppresses the mechanisms related to blood-brain barrier degeneration.\textsuperscript{27, 32-34}

Most of these mechanisms are effective during the ischemia and reperfusion period, but cooling also has a long-lasting neuroprotective effect.\textsuperscript{33} Protection has also been observed with delayed cooling.\textsuperscript{31} Delayed cooling may be effective by attenuating events triggered by a secondary window.\textsuperscript{33}
Applications of therapeutic hypothermia after cardiac arrest

TH is recommended for all comatose patients with witnessed CA when the first recorded rhythm is ventricular tachycardia (VT) or ventricular fibrillation (VF), but should also be considered for other first recorded electrocardiogram (ECG) rhythms if active treatment is decided. Before cooling, all patients need to be intubated, mechanically ventilated and sedated.\(^7\), \(^12\), \(^13\)

**Phases of treatment**

TH is usually divided into three phases: induction, maintenance and rewarming. Induction should be carried out as quickly as possible to minimize the risk of side effects. During the maintenance phase, the temperature should be controlled at the target temperature with minor fluctuations.\(^35\)

Well-controlled hypothermia has been shown to correlate with favourable neurological outcomes.\(^36\) Cooling below 32°C should be avoided.\(^37\) The rewarming phase should be slow and controlled at no more than 0.2-0.5°C/hour to avoid rapid changes of metabolism and cerebral blood flow.\(^35\)

However, in a retrospective analysis, no significant difference in poor outcome was found between rewarming at a rate >0.5°C/hour compared to rewarming <0.5°C/hour.\(^38\) The same study, found no association between fever after rewarming and poor outcome,\(^38\) while other have found fever post-CA associated with unfavourable outcome.\(^15\)-\(^17\)

**Duration and initiation**

The optimal duration of TH is unknown,\(^32\), \(^39\) but the time used in several studies ranges from 12 to 24 hours.\(^30\), \(^31\), \(^40\)-\(^43\). Recommendations in clinical guidelines are also that TH should be continued for 12-24 hours.\(^7\), \(^12\), \(^13\). The optimal time at which to initiate TH is also unknown. Favourable neurological outcomes have been shown when the target temperature is achieved 8 hours from CA,\(^31\) and in a registry-based report, time to initiation and time to target temperature had no significant association with outcome.\(^44\) In another study, early achievement of target temperature was an independent factor for good outcome.\(^45\) In an animal study, good neurological outcomes were found when TH was initiated within 4 hours from CA, and there was no difference in outcome by duration of TH (24 versus 48 hours), though the surviving neuron count was greater after 48 hours TH than after 24 hours.\(^46\)

**Target temperature**

The target temperature used in randomized clinical trials has been 33°C\(^30\) or 32-34°C.\(^31\) The recommendation in the guidelines is a target temperature of 32-34°C.\(^7\), \(^12\), \(^13\). The optimal target temperature has not yet been established. A recently published study compared 33°C to 36°C and found no difference in neurological outcome or mortality.\(^16\)
**Cooling methods**

Several methods have been described, but the ideal method for TH is not known. For induction, intravenous infusion of ice-cold fluid (30-40 ml/kg) can easily be used and is rapid and effective.\(^{47-50}\) On the other hand, pre-hospital cooling with cold infusion have shown increased rates if rearrests before admission to hospital,\(^{51}\) and in an animal model of CA, intravenous volume was associated with decreased coronary artery perfusion pressure.\(^{52}\)

Cold infusion alone has been shown to be inadequate for maintaining hypothermia.\(^{47}\) Different cooling methods and devices for maintaining TH have been described. For surface cooling, different devices can be used, such as ice packs, which are inexpensive, safe and easy to use.\(^{30, 40}\) Another type of surface cooling is with special pads that are described as feasible, fast and safe to use.\(^{53}\) Special suits and blankets with circulating air or water are also available.\(^{54, 55}\) Even caps/helmets for TH are described.\(^{56}\) A combination of different surface cooling devices can be used to reach target temperature as fast as possible.\(^{54, 57}\) Endovascular cooling – cooling with a closed-loop endovascular system and a catheter usually placed in the femoral vein – has been described as feasible, safe and as resulting in a steady temperature.\(^{49, 58, 59}\) Transnasal cooling is another method tested in studies for both induction and maintenance, either with gas or cold water circulating in balloons.\(^{60, 61}\)

Among these methods, surface cooling is generally considered the least expensive and is the most widely used. However, there is no research indicating which TH methods are superior.\(^{13}\) Two studies that compared surface cooling with endovascular cooling found no difference in cooling rate, survival and neurological outcome.\(^{62, 63}\) All methods have their strengths and weaknesses, therefore it is important for each unit to use a method that suits its logistics and that the personnel are familiar with.\(^{64}\)

**Physiological side effects**

During TH, different possible side effects may occur. It is important to be aware of these side effects as they may reduce the positive effects of TH if they are not prevented.

Shivering is common, especially during induction. Shivering increases oxygen consumption and metabolic rate and makes it more difficult to rapidly decrease the body temperature to the target temperature. The most important method of avoiding shivering is to use sedation and analgesia in sufficient amounts. Another side effect is hypovolemia due to cold diuresis, which can result in hypotension and hemodynamic instability.\(^{35}\) Bradycardia is seen during TH and is a positive effect, thus usually not necessary to aggressively treat.\(^{65, 66}\) The risk of severe arrhythmias is low at temperatures >30°C. Cooling can also affect electrolyte levels with loss of potassium, sodium, magnesium, phosphate and calcium. This involves a combination of intracellular shift and tubular dysfunction. Electrolyte levels should be kept
in the normal range to avoid complications related to low levels. During rewarming, there is a risk of hyperkalemia due to extracellular shift. TH causes a decrease in insulin sensitivity and secretion. To maintain normoglycemia, supply of insulin may be required during the induction and maintenance phases, but the need for insulin decreases during rewarming. A decrease in metabolic rate affects drug clearance. A decrease in the metabolism alters CO₂ production, and adjustment of ventilation is needed to avoid hypocapnia. TH causes mild metabolic acidosis, which in most patients does not require treatment. Other side effects that may occur are impaired coagulation and increased risk for infection.

Adverse events that have been reported after TH are hyperglycemia, electrolyte disorders, seizures, arrhythmias and pneumonia. Less frequent are bleeding and sepsis. Pneumonia is a frequent problem in ventilated CA patients and TH is a risk factor. One systematic review found that most adverse events and complications after CA do not differ between hypothermia and nonhypothermia groups, except for hypokalaemia and arrhythmias. Adverse effects of TH can be controlled and treated with extensive and proper intensive care.

Prognostication
The prognosis and the long-term outcome are difficult to predict in the early phase after CA, and prognostication may be performed not earlier than 3 days post-CA. Since TH has become a recommended treatment in the post-CA care, prognostication is delayed until 72 hours after normothermia. TH and sedation affect awakening, due to the prolonged metabolism of drugs and the effect of hypothermia.

The natural course of recovery after hypoxic brain injury
Neurological recovery follows a certain pattern and is dependent on the severity of the hypoxic brain injury. Initial recovery comprises a return of brainstem functions, with cranial nerve reflexes and spontaneous breathing. This is followed by return of activity in deeper structures of the brain, with defensive reactivity, and eventually consciousness, with gradual return of eye-orientation, speech, motor functions, orientation and memory function. The brainstem is less sensitive to hypoxia, and recovery of brainstem functions, like breathing, is common even in patients with severe hypoxic brain injury.
Prediction of neurological outcome

Several methods for predicting the long-term neurological outcome after CA have been reported: clinical neurological examination, neurophysiological examination (electroencephalogram (EEG), somatosensory evoked potentials (SSEP)), imaging (magnetic resonance imaging (MRI), computed tomography (CT)) and biomarkers. For prognostication, a continuous evaluation of the patient’s prognosis is needed and a combination of predictors is recommended.

Clinical neurological examination

Clinical neurological examination should include brainstem reflexes, motor response and presence of myoclonus. Signs with high specificity for poor outcome when examining of brainstem reflexes are: bilateral absence of pupillary reflex to light, bilateral absence of corneal reflexes and no motor response or an extension pattern to pain stimuli. Observed spontaneous myoclonus is associated with poor outcome, but neurological recovery cannot be ruled out.

Neurophysiological examination

EEG is the recording of electrical activity generated from voltage changes across neuronal membranes and is a marker of neuronal activity. It is recommended that EEG be performed early in comatose patients either intermittently (standard EEG) or continuously (cEEG). EEG is used to detect seizures and the EEG pattern has a prognostic value.

SSEP involves stimulation of a peripheral nerve, usually the median nerve at the wrist, and the response is registered at the plexus brachialis, brainstem and cortex. Bilateral absence of cortical response is a predictor of poor outcome. The examination should be performed when the patient has reached normothermia and can be used with good reliability even when the patient is sedated.

Imaging

CT-scan is recommended in the early phase after CA to detect differential diagnoses to the CA, such as intracranial haemorrhages or high cervical fractures after trauma. Brain swelling may be present after hypoxic brain injury and is detectable with CT scan. The prognostic value of CT scan is limited and is not supported in the guidelines.

MRI 3-5 days after CA is a more sensitive tool than CT scan for detecting hypoxic brain injury. Knowledge of the prognostic value of MRI and its independent value as a predictor of outcome is still limited. The examination is not recommended as a routine in guidelines.
Biomarkers

Biomarkers can be proteins released into the cerebrospinal fluid after brain injury and through the blood-brain-barrier into systemic circulation. An ideal biomarker of brain injury should have certain properties for prediction of outcome. It should originate specifically from the damaged neurons in the brain, provide information about the severity of the brain damage, have high specificity and sensitivity, be easy to sample and analyze, be independent from the effect of sedative drugs and be able to predict outcome in an early phase. Regarding the state of knowledge today, there are limitations in the reliability of biomarkers. Different cut-off values for predicting poor outcomes are presented and the influence of hemolysis in the sample can affect the response. Another factor is that levels might differ among laboratories.

The most commonly studied biomarkers of brain injury after CA are neuron-specific enolase (NSE) and S100B. Other brain-specific markers that have been investigated in CA patients are Glial fibrillary acidic protein (GFAP), Amyloid beta (Aβ), brain-derived neurotrophic factor (BDNF), neurofilament light (NfL) and neurofilament heavy (NfH). Given post-CA syndrome and that a sepsis-like syndrome occurs after CA, inflammatory response and procalcitonin have been investigated as possible part of the prognostication of outcome.

NSE

NSE is a dimeric enzyme that is present in neurons and neuroendocrine cells. NSE is also present in erythrocytes and platelets, which is a source in the clinical setting where hemolysis may affect the analysis. Hypoxic brain injury releases NSE into the circulation, and its half-life is estimated to be 24-30 hours. Following CA, the serum concentration usually rises after 24 hours to a high sustained level for 48-72 hours post-CA. Elevations of NSE after CA are associated with poor outcome in comatose patients. Cut-off values with 0% false positive rate (FPR) for predicting poor outcome are conflicting and show great variation. In one study, changes in elevation of NSE between admission and 48 hours post-CA were shown to be associated with poor outcome. At least two samples should be analysed to evaluate the trend.

S100B

S100B is an intracellular calcium-binding protein that is expressed particularly in astroglial cells in the white matter of the brain. S100B has a short half-life, about 2 hours, which means it has its highest sensitivity during the first 24 hours after hypoxic brain injury. Its serum levels may also be influenced by release from fat and skeletal tissues. Serum levels of S100B have been examined in relation to outcome in several studies involving CA pa-
tients. Values of 0% FPR in S100B have also been reported to show great variation. In the evaluation of this marker, it is also important to look at changes over time.

**Glial fibrillary acidic protein**

GFAP is a filament of mature astrocytes of the central nervous system. It is thought that GFAP is produced almost exclusively by astrocytes, making it specific to the brain. GFAP has been shown to be a biomarker of both traumatic brain injury and stroke. In patients with ischemic stroke, leakage of GFAP into peripheral blood is considered an indicator of brain damage. The process of leakage into the circulatory system is explained by an increased brain-blood gradient. In CA patients, the levels of GFAP tend to increase in patients with poor neurological outcome.

**Withdrawal of care**

The most common cause of death after admission to ICU following a CA is neurological injury. In patients treated with TH post-CA, the majority died after the decision to withdraw of life-sustaining treatment based on a prediction of poor neurological prognosis due to severe hypoxic brain injury. In a retrospective study of patients who were conscious despite hypoxic brain injury after CA, with or without TH, 6% achieved good functional outcome and 80% were alive in a vegetative state or with severe brain injury 4 months post-CA. Withholding and withdrawing of life support are ethically similar and entail a complex decision for staff and involve relatives. The decision to limit and withdraw care should not be based on the results of a single prognostication tool and should be postponed until at least 72 hours after rewarming.

**Outcome after cardiac arrest**

The number of survivors after CA has increased during the past decade. It is not only survival that is an important consideration, but also residual impairments and disability after CA in determining post-resuscitation care. In survivors after CA, neurological outcome, anxiety, depression, decreased quality of life (QoL), posttraumatic stress disorder (PTSD) and cognitive impairments have been reported in varying degrees. Having been seriously ill and treated in an ICU often involves impacts on physical and psychological functions. The prevalence of such problems and impairment of QoL after critical illness and ICU treatment is high. The individual’s QoL should be an outcome measure in studies of CA survivors. QoL is defined as the individual's own evaluation of his/her physical and mental health as well as satisfaction with his/her social situation.
HRQoL measures are used to show how health status, such as illness or disability, affects QoL, and HRQoL refers to how the individual’s wellbeing may be affected over time by a disease or a disorder.\textsuperscript{122}

CA arrest survivors are often seen as “cardiac patients”, but also need to be seen as “neurological patients” due to the potential hypoxic brain injury that may affect the long-term outcome.\textsuperscript{116}

Neurological outcome

Reports on neurological outcome after CA, often use the Pittsburgh Cerebral Performance Categories (CPC) scale,\textsuperscript{123} which is also recommended in guidelines.\textsuperscript{5} The scale ranges from 1 to 5 and the different levels of function are presented in Table 1. The CPC scale is usually dichotomized into good or poor outcome, where CPC 1-2 corresponds to good outcome and CPC 3-5 to poor outcome. The ability of the CPC scale to assess patients’ outcome regarding both physical and psychological problems is limited.\textsuperscript{124, 125} However, in 2002, two randomized controlled studies showed improved neurological outcome after CA in patients treated with TH.\textsuperscript{30, 31} A Cochrane review found that TH seem to improve neurological outcome compared to standard post-resuscitation care.\textsuperscript{126}

Table 1. \textit{Cerebral Performance Categories (CPC) scale.}

<table>
<thead>
<tr>
<th>CPC score</th>
<th>Function level</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPC 1</td>
<td>Good cerebral performance; conscious, alert, able to work</td>
</tr>
<tr>
<td>CPC 2</td>
<td>Moderate cerebral performance; conscious, can carry out independent activities</td>
</tr>
<tr>
<td>CPC 3</td>
<td>Severe cerebral disability; conscious, dependent on others for daily support</td>
</tr>
<tr>
<td>CPC 4</td>
<td>Coma or vegetative state</td>
</tr>
<tr>
<td>CPC 5</td>
<td>Death</td>
</tr>
</tbody>
</table>

Health-related quality of life

HRQoL is negatively affected and related to cognitive dysfunctions in CA survivors. In one review, cognitive problems, in particular memory problems, were found in between 6-100% of CA survivors.\textsuperscript{116} Other factors affecting HRQoL are fatigue, emotional problems, PTSD and difficulties in daily activities.\textsuperscript{127} Results from previous studies on HRQoL after CA are conflicting. Some have reported decreased HRQoL after CA, though not always statistically significant differences from the general population.\textsuperscript{128-130} In one study, HRQoL after CA was lower than for the general population.\textsuperscript{131} Others have shown that CA survivors have acceptable or good HRQoL, though not necessarily the same HRQoL as before the CA.\textsuperscript{115} Studies comparing CA patients treated with or without TH found no difference in cognitive function or HRQoL.\textsuperscript{128, 132} One study, comparing CA patients with or
without hypoxic brain injury, found no difference in HRQoL between the groups. In any event, CA survivors stated they were satisfied with life as a whole.

Anxiety and depression
Depressive symptoms are common in ICU survivors in general and may negatively impact HRQoL. In CA patients, anxiety and depression have been shown to be strongly related to HRQoL. Anxiety and depression are present in CA-survivors, but figures of the occurrence of anxiety and depression vary across studies investigating this problem. The proportion of patients affected varies between 13-61% for anxiety and 14-45% for depression.

Relatives
Relatives of critically ill persons
The experience of being a relative of a person who has been critically ill and hospitalized at an ICU is described as one of chock, stress and of feeling that time has stood still. For the relative, the critical situation creates anxiety, uncertainty and a feeling of alternating between hope and despair. Having a close family member or friend admitted to the ICU is unexpected and stressful as the event involves threats of death or serious injury. It qualifies as a traumatic stressor that may cause PTSD. Relatives of ICU patients have reported high levels of PTSD shortly after admission to ICU, and PTSD symptoms may remain for several months. Increased levels of anxiety and depression are also reported in relatives of ICU patients.

The need for information about the severely ill person is what relatives have in common and what is often revealed in studies. It appears to be the greatest need for relatives of the critically ill patient. They want to get adequate and honest information in an understandable manner, and information makes it easier for them to accept and understand what has happened. Relatives need to feel hope, even if they understand that the situation is serious. Feeling there is hope that the outcome will be good gives relatives strength. They need to be assured that the severely ill person is receiving the best possible care from competent and committed personnel. Support to relatives is necessary, and the most important support comes from other family members with whom they are able to share their experiences, feelings and decision-making as well as deal with practical matters.

Relatives are of great importance to the severely ill patient during hospitalization at the ICU because they motivate, support and acknowledge the
Patient. Relatives want to be close to the patient and to see the patient regularly. They want flexible visiting hours, and they feel supported when they are welcome at any time.

Relatives of cardiac arrest patients

Relatives’ experiences of their next of kin suffering a CA are described as a feeling that one’s entire sense of normality has come to an end. The event is also described as strong and chaotic. Feelings of fear, panic, shock and agitation are mentioned. Relatives often have difficulties seeing the warning signs before the CA, which is described as unexpected. Relatives describe the period of waiting for the ambulance to arrive one of time being on hold. In cases where relatives performed CPR, in retrospect they are worried about whether they performed it correctly, which may cause guilt if the patient stay unconscious. In the ICU, during the TH, relatives have described the patient as cold, lifeless and hard to recognizable. The prognosis and long-term outcome are difficult to predict in the early phase after CA, and this is a period of great anxiety for the relative. These relatives need information and support, just as all relatives of critically ill patients do.

Rationale for the thesis

An increasing number of people survive CA, and therefore it is appropriate to acquire more knowledge about post-resuscitation care. As we have seen in the literature review, patients who have ROSC after CA have a complex illness and are challenging to care for, both in the ICU and the subsequent care. This places high demands on staff, when not only patients but also family members need to be taken care off. Increased knowledge may improve survival and survival with good outcome. With increased knowledge, there are also opportunities to improve care, support people who have survived CA and meet their and their relative’s needs in daily life.

This research was inspired during the clinical practice in the ICU, caring for CA patients and their relatives. The care and the meeting with patients and relatives raise several questions. In this thesis, we focused on the following questions: How effective was the TH method used in the clinic? Is it possible to predict which patients will have a good outcome? What is the patient’s outcome and how have relatives experienced the situation?

During the first inclusion period (Paper I), TH was a new treatment for CA patients and it was important to determine the effectiveness of the method used in the current ICU. By this time, only limited results were available.
on the described cooling method. To improve prognostication, biomarkers are a promising early predictor. Of the biomarkers investigated in this thesis, when planning, one has not been analyzed earlier in this group of patients and further evaluation is needed for the other two more commonly studied biomarkers. To evaluate TH in patients after CA, it is important to follow them over time. TH is aimed at reducing and preventing brain damage after CA, and therefore patients' HRQoL and physical and psychological functions after treatment are important to investigate. At the time of planning the research, there were no studies on how CA survivors treated with TH rate their function and HRQoL. To meet the relatives' need for information and support, it is necessary to find out what their needs are. When planning the study, we could not find any published studies focused on relatives of CA patients who had been treated with TH.
Aims

The overall aim of the thesis was to study post-resuscitation care of CA patients, with a focus on therapeutic hypothermia treatment, outcome up to six months and relatives’ experiences during the hospital stay.

**Paper I**
To assess hypothermia treatment with cold, 4°C intravenous crystalloid infusion combined with ice packs during induction, maintenance and rewarming for temperature control.

**Paper II**
To investigate the association of serum GFAP levels, determined using a novel, fully automated immunochemical method, at different time points post-CA with outcome and compare its sensitivity and specificity to NSE and S100B.

**Paper III**
Firstly, to investigate whether there were any changes in anxiety, depression and HRQoL between hospital discharge and one and six months post-CA in patients treated with TH. Secondly, to study possible relationships between anxiety, depression and HRQoL.

**Paper IV**
To describe relatives’ experiences during the acute phase when a next of kin has survived CA treated with TH at an ICU.
Materials and methods

In this thesis, both quantitative and qualitative approaches have been used, based on the aim of the studies. An overview is presented in Table 2.

Table 2. Overview of study design, study population, number of participants and analysis.

<table>
<thead>
<tr>
<th>Paper</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>Single-centre, prospective observational study</td>
<td>Multi-centre, prospective observational study</td>
<td>Multi-centre, prospective observational study</td>
<td>Multi-centre, descriptive with a qualitative approach</td>
</tr>
<tr>
<td>Participants</td>
<td>n=38</td>
<td>n=125</td>
<td>n=26</td>
<td>n=20</td>
</tr>
<tr>
<td>Analysis</td>
<td>Descriptive statistics</td>
<td>Descriptive and analytic statistics</td>
<td>Descriptive and analytic statistics</td>
<td>Qualitative content analysis</td>
</tr>
</tbody>
</table>

In Figure 2, an overview is provided of what time after the CA each data collection occurred.
Figure 2. Measure occasions for data collection after CA. Grey box indicates the period of hypothermia treatment, including rewarming.

Paper I

This was a prospective observational study of a cohort of CA arrest patients treated with TH at the ICU and was designed to evaluate a method for hypothermia treatment.

Settings and participants

The study comprised patients treated with hypothermia after CA at the ICU at Uppsala University Hospital, Uppsala, Sweden, between December 2004 and June 2007. The patients were eligible for inclusion if they were still comatose after successful ROSC. Both patients with in-hospital cardiac arrest and out-of-hospital cardiac arrest (OHCA) were included, also independent of first registered ECG rhythm. Patients were excluded if they were under 18 years of age, if hypothermia treatment was started more than 6 h after cardiac arrest, if the temperature was below 34°C on admission to the ICU, or if the cardiac arrest was a consequence of trauma.
Cooling method

Hypothermia treatment was induced by infusion of a 4°C intravenous saline, in a planned volume of 30 ml/kg at a rate of 100 ml/min via two peripheral intravenous catheters. To complete induction and for maintained cooling, ice packs were applied in the groins, axillae and along the neck and were changed when necessary to allow continuous cooling. The ice packs used were saline infusion bags of 250 ml, which were stored in the freezer of the emergency department or the ICU. The ice packs were covered with a pillowcase to prevent cold injury on the patient’s skin. During the cooling treatment, the temperature was adjusted by applying or removing ice packs. The planned duration of hypothermia treatment was 24 hours, and it was estimated that the first two hours after CA would be taken up by transportation to hospital and decision-making regarding hypothermia treatment. The target temperature of 32-34°C was therefore maintained for up to 26 hours after the estimated time of CA. Passive rewarming at 0.5°C/hour started after 26 hours and it was expected that a temperature of 36°C, which was considered the normal core temperature, would be reached within 8 hours. If the temperature increased too rapidly, the patient was given a bolus injection of a sedative, the blankets were removed, and the ice packs were applied again.

Treatment protocol

The patients were sedated and mechanically ventilated during TH. If the induction of TH went slowly or if there were any signs of shivering, the sedation and analgesia were increased. Muscle relaxation was only used if necessary as a bolus injection and subsequently, if required, as an infusion. The goal was to discontinue administration of muscle relaxant when the target temperature for TH was reached. After rewarming, the sedation was terminated. The treatment protocol had defined goals for factors that are generally considered important for critically ill/CA patients, but was adjusted for TH.

Data collection and monitoring

Core temperature was measured continuously in the urinary bladder and recorded on the patient’s chart every 15 min up to 44 h after the cardiac arrest. Furthermore patients were monitored routinely for continuous blood pressure, central venous pressures, ECG, respiration, oxygen saturation and diuresis. Arterial blood samples were drawn every 90-120 min for measurement and analysis of blood gases, glucose and electrolytes. Complete blood counts were taken every 24 h. Neurological evaluation was carried out with the Reaction Level Scale (RLS 85) or Glasgow Coma Scale (GCS) on arrival. The neurological outcome was assessed using the CPC scale (Table
at discharge from the ICU and 6 months after cardiac arrest. The assessment after 6 months was conducted by a journal review or a phone call.

Statistical analysis
Descriptive statistics and demographic data are presented as means, standard deviations, ranges, percentages and numbers.

Paper II
This paper was a prospective observational study performed in three ICU departments to investigate levels of biomarkers in CA patients.

Settings and participants
The study was conducted in three hospitals, one university hospital and two general county hospitals, during the period from May 2008 to May 2012. Eligible for inclusion were CA patients with successful ROSC, systolic arterial blood pressure ≥ 80 mmHg > 5 min, unconscious with a GCS score < 8, age > 18 years for whom TH was induced. The decision to start TH was taken for all patients, irrespective of the first registered ECG rhythm or whether the CA occurred in or out of hospital. TH was induced by infusion of a 4°C intravenous saline, in a planned volume of 30-40 ml/kg. To maintain cooling, all hospitals used external cooling, either ice packs or cooling suits depending on hospital-specific routines. Rewarming at a rate of 0.5°C/hour was used and 36°C was considered the normal core temperature. The patients were cooled to 32-34°C for 24 hours. Before cooling, all patients were sedated, intubated and mechanically ventilated according to local ICU guidelines for severely ill patients adapted for TH after CA.

During the inclusion period, 242 CA patients were admitted to the ICUs, 209 underwent TH, and of these, 125 were included in the study. Sixty-three patients survived until hospital discharge, 38 died before ICU discharge and 24 died in the medical ward. The main cause of death was cerebral (n=39) and cardiac (n=16). Two patients died between one and six months, both in a new CA. One had reach CPC 1 and the other CPC 3.

Data collection
Blood samples for biomarkers were collected as soon as possible upon arrival to the ICU and at 24, 48, 72, 96 and 108 hours after CA from a peripheral artery or vein. In patients who were provided with a catheter in the jugular bulb, blood samples were collected there at the same time points. The sam-
amples were stored in a -70°C freezer, and analysed at the same time after the study period.

Medical background variables, information about the CA and data on temperature management were retrieved from the medical chart. Functional outcome was assessed using the CPC scale (Table 1). \(^\text{123}\)

**Analysis of biomarkers**

Serum levels of NSE and S100B were measured using a Cobas e601 instrument and NSE and S100B reagent kits as described by the manufacturer (Roche Diagnostics, Penzberg, Germany). For detection of hemolysis, a serum measurement index of hemolysis (Sindh) was used. Serum GFAP was measured using the non-commercial Elecsys® GFAP prototype test on a Cobas e411 instrument (Roche, Penzberg, Germany). In the first step, biotin- and ruthenium-labeled monoclonal anti-GFAP antibodies are combined with 50µl of sample and incubated for 9 minutes. In the second step, streptavidin-coated magnetic microparticles are added and the mixture is incubated for an additional 9 minutes. After the second incubation step, the reaction mixture is transferred into the measuring cell where the beads are captured on the surface of an electrode by a magnet. The unbound label is removed by washing the measuring cell. In the last step, voltage is applied to the electrode in the presence of a tri-propylamine (TPA)-containing buffer, the resulting electrochemiluminescent signal is recorded by a photomultiplier and the GFAP concentration is derived from a calibration curve. Because no acknowledged reference method is available at present, the method has been standardized by weighing pure human GFAP in analyte-free serum matrix. Three internal samples based on human serum matrix spiked with human GFAP low (< 5ng/ml), medium (20 – 30ng/ml) and high (> 50ng/ml) were used for quality control during the assay. The within- and between-run precisions were 1.1-1.9% and 2.7-4.2%, respectively.

**Statistical analysis**

The scores were dichotomized into good (CPC 1-2) and poor (CPC 3-5) neurological outcome. The continuous data were not normally distributed, and therefore non-parametric statistics were used. Descriptive statistics were used to present participants’ demographic and medical characteristics. The Mann Whitney U-test (continuous variables) and Chi-squared test (categorical variables) were used to compare demographic and medical characteristics between the good and poor outcome groups. To test differences between the good and poor groups for GFAP, NSE and S100B at each time point, the Mann Whitney U-test was used. The incremental predictive value of GFAP, S100B and NSE was evaluated using logistic regression models and presented with area under the receiver operating characteristic (ROC) curve (AUC).
Sensitivity and specificity for specific cut-off values were derived using ROC. The Wilcoxon signed rank test was used for analysis of the difference between blood samples from a peripheral artery or vein and samples from the jugular bulb. P-values <0.05 (two-tailed) were defined as statistically significant. All statistical analyses were performed using SPSS version 21 (SPSS Inc. Chicago, IL, USA).

**Paper III**

Paper III is a quantitative study designed to investigate HRQoL, anxiety and depression in CA patients who were treated with TH and survived until 6 months.

**Settings and participants**

This multicentre prospective observational study was performed at one university hospital and two general county hospitals during the period 2008 to 2012. Patients considered for inclusion had suffered a CA, been treated with TH and survived until hospital discharge with a good functional outcome defined as being able to complete the questionnaires. The patient had to be discharged from hospital within one month post-CA and to answer the questionnaires at all three occasions. Participants needed to be 18 years or older and have sufficient knowledge of the Swedish language to complete the questionnaires. Out of the 63 patients surviving until hospital discharge, 54 answered the questionnaires on at least one of the occasions. Twenty-six patients were able to answer the questionnaires at all three occasions and could thus be included in the study. Figure 3 is shows the inclusion process.

![Figure 3. Flow chart over participants in Paper III.](image)

**Data collection**

Follow-up data were collected at three occasions. The first occasion was at hospital discharge (M1), which occurred on average 1.9 (median 1.8, min 1.0, max 3.5) weeks post-CA. The second occasion (M2) was at one month post-CA and the third (M3) after six months. At M1, one study manager met
the patient; at M2 the questionnaires were sent by post after telephone contact. At M3 a study manager again met with the patient. Functional outcome was assessed using the CPC scale (Table 1). The standardized questionnaires used were the Hospital Anxiety and Depression Scale (HADS), the Euroqol (EQ5D) and the Short Form 12 (SF12). Medical variables were collected from the medical chart. Socio-demographic variables prior to the CA were collected by self-report at M1. Data on participants’ working situation and whether they had been in contact with any health service were collected at M3.

**HADS**

HADS is a 14-item standardized questionnaire designed to assess mood disorders in non-psychiatric hospital patients. The questionnaire is divided into two subscales measuring signs of anxiety and depression. The highest possible score for each subscale is 21, higher scores representing more emotional problems. A score of 0-7 for each subscale indicates no anxiety or depression, 8-10 mild to moderate anxiety or depression, and a score of 11 or higher indicates risk for occurrence of anxiety disorders or depression requiring medical treatment.

**EQ5D**

The EQ-5D health status standardized questionnaire is a self-reporting questionnaire and comprises 5 questions – each with 3 levels. Level one represents no problems, level two some problems, and level three extreme problems. The 5 questions correspond to 5 health domains: pain, mood, mobility, self-care and daily activities. EQ5D can be converted into a single summary index, where the highest possible index for HRQoL in all domains is 1.00. The Euroqol visual analogue scale (EQ-VAS) is a measure of self-rated overall health status and ranges from 0-100.

**SF12**

The SF-12 is a validated standardized questionnaire composed of 12 items divided into two components, the mental component score (MCS) and the physical component score (PCS), which are calculated to summarize mental and physical status, respectively. The patients estimate their HRQoL during the past week. The components are standardized with scores ranging from 0 to 100, where a higher score represents better experienced HRQoL. A norm-based standardized score with a mean of 50 and standard deviations of 10 has been computed for the general population in United States. A MCS or PCS summary score ≤40 represents moderate to low HRQoL. SF12 has been validated in a Swedish population and the mean values are MCS 52.8 and PCS 50.2.
Statistical analysis

Descriptive statistics were used to present participants’ demographic and medical characteristics as well as central tendencies and distributions of the variables covered in the questionnaires. To compare the study population with the excluded group that did not answer the questionnaires at all three occasions, Mann Whitney U-test and chi-squared test were used. Owing to the small sample size, Friedman’s test was used to conduct analysis of variance across the three measurement occasions. The Wilcoxon signed rank test (two-tailed) was used for post-hoc analysis of the difference between two measurement occasions. Spearman’s rank correlation coefficient (two-tailed) was calculated to investigate relationships between anxiety and depression and HRQoL. Because multiple tests were used for comparison and correlation, a p-value ≤ 0.01 (two-tailed) was considered statistically significant. The reliability of the questionnaires was expressed as Cronbach’s α coefficient. Data were recorded and statistical analyses were performed using SPSS version 21 (SPSS Inc. Chicago, IL, USA).

Paper IV

In Paper IV, a qualitative methodology was used to describe relatives’ experiences during their next of kin’s hospital stay after surviving a CA.

Setting and participants

The study took place at three hospitals in central Sweden, one university hospital and two general county hospitals. Twenty relatives of patients who had survived a CA and been treated with TH were included in the study during the period May 2008 to June 2010. Purposive sampling of relatives was based on age and gender to achieve as much variation as possible. Table 3 is shows demographic data on the participants.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age</th>
<th>Relation to the patient</th>
<th>Working situation at the time of the CA</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Women</td>
<td>20-70 years</td>
<td>10 Husband or wife</td>
<td>13 Worked full time</td>
</tr>
<tr>
<td>7 Men</td>
<td>(mean 52)</td>
<td>3 Partners</td>
<td>4 Worked part time</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 Children</td>
<td>3 Retired or sick-listed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 Parent</td>
<td></td>
</tr>
</tbody>
</table>
Data collection

Data were collected using a semi-structured interview guide covering how the relatives experienced their next of kin’s CA and TH, support and information during the stay in hospital, how everyday life had changed and how they viewed the future. An interview guide was developed by consensus within the research group. A pilot interview was performed to test the usability of the interview guide, which was found to be feasible. Clarifying questions were used such as “What do you mean?”, “How did you feel then?” and “What did you think then?” The interview was conducted at the time when the patient was discharged from hospital, 1.5 to 6 weeks post-CA. The interviews were recorded and lasted from 30 to 60 minutes. The interview took place in a separate room at the hospital or in the relative’s home, depending on the relative's wishes. Four of the interviews were conducted over the telephone because of the distance involved. Three ICU nurses performed the interviews, one had experience in the method and supervised the others in data collection.

Data analysis

The interview text was systematically analysed using qualitative content analysis. The method was developed to describe the content of communication and was originally a quantitative method. Qualitative content analysis is defined as a method for analysing a text in a systematic way and drawing replicable and valid inferences from the text to their context, focusing on differences and similarities, thus demonstrating variability and diversity and giving the context a meaning. The descriptive level of qualitative content analysis, the manifest content, is described in categories or subcategories, and the underlying meanings are used to create themes, representing the latent content. In this study, the latent content was used and the process of the analysis was as following steps:

1. The interviews were transcribed verbatim.
2. The text was read several times in order to gain an overall impression.
3. The text was divided into meaning units in line with the aim of the study. A meaning unit could consist of a few words or several sentences.
4. The meaning units were condensed and given a code.
5. Codes that expressed related meanings were grouped together into categories.
6. Categories with similar content and underlying meaning were sorted into the same theme.

Throughout the process, the authors went back and forth between the interviews, codes, categories and themes to validate the findings. The first author continuously discussed the analysis process with the supervisor.
Ethical considerations

The studies were performed according to the Declaration of Helsinki\textsuperscript{167} and reviewed and approved by The Regional Ethical Committee in Uppsala (Reg. no. 2004:M-207 and 2007/307). The participants were treated with respect and their interests were prioritized. Data collection was carried out with respect for integrity. The participants received written and oral information about the purpose of the study. They were told that participation was voluntary, that they were free to withdraw at any time and that full confidentiality was guaranteed. In Paper I-II, the patients were unconscious when they were included, so the information was given to and consent first obtained from a relative. Later, when the patients were considered competent, they received information and gave their informed consent, then they were also asked to participate in the study for Paper III. In Paper IV, the participants gave their informed consent.

No medical risks were anticipated due to the study participation. The cooling method evaluated in Paper I had already been implemented in clinical practice. The samples of biomarkers were taken at the same time as ordinary blood samples and the amount of blood was small. The research team has extensive experience of conducting research with and caring for CA patients. This meant they had both the knowledge and preparedness to handle any questions or concerns the participants might have had. Because participants may have felt the researcher having access to their personal data was a violation of their personal integrity, the voluntary and confidential nature of the study was emphasized as well as the fact that the results would be presented at a group level and made anonymous.
Results

Paper I
During the 30-months period of the study, 38 of the 45 patients treated with TH after CA were included. The mean age was 60 (22-82) years, and most were men (n=25, 66%). There were more frequently OHCA (n=30, 79%), and most were witnessed (n=28, 74%). First registered ECG rhythm was VF in 16 (42%) of the patients, 12 (32%) had asystole, 6 (16%) pulseless electric activity (PEA) and 4 (10%) other rhythms.

Temperature control
In all patients, the target temperature of 32-34°C was attained and within 279±185 (60-650) minutes from the estimated time of CA. Time from cooling start to target temperature was 216±177 (10-570) minutes. Time for rewarming who started 26 hours after CA until patient reached 36°C was 8.2±3.2 (1.2-16.5) hours. The volume of cooled saline infusion during induction of TH was 42±12 (20-70) ml/kg. In nine patients (24%), the temperature dropped below 32°C during a period ranging from 15 minutes to 2.5 hours. No patient exceeded the upper limit of 34°C of the target temperature range during TH. Rebound hyperthermia (>38°C) occurred in eight patients (21%), and the mean temperature in these patients 44 hours after CA was 38.5 ±0.6 (38.1-39.8)°C. The core body temperature is presented in Figure 4.
Figure 4. Core body temperature in degrees Celsius (C) expressed as mean ±SD during induction, maintenance and rewarming. Time 0 represents estimated time of CA.

Outcome

At discharge from ICU, the neurological outcome was good in 10/38 (26%) participants and after 6 months in 17/38 (45%). Table 4 is shows neurological outcome from the study population, including the first registered ECG rhythm.

Table 4. Neurological outcome at discharge from ICU and after 6 months.

<table>
<thead>
<tr>
<th></th>
<th>CPC 1-2</th>
<th>CPC 3-4</th>
<th>CPC 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge from ICU (n=38)</td>
<td>10 (26)</td>
<td>16 (42)</td>
<td>12 (32)</td>
</tr>
<tr>
<td>VF* (n=16)</td>
<td>6 (37)</td>
<td>7 (44)</td>
<td>3 (19)</td>
</tr>
<tr>
<td>Asystole, PEA*</td>
<td>3 (17)</td>
<td>7 (39)</td>
<td>8 (44)</td>
</tr>
<tr>
<td>Asystole, PEA*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months post-CA (n=38)</td>
<td>17 (45)</td>
<td>2 (5)</td>
<td>19 (50)</td>
</tr>
<tr>
<td>VF* (n=16)</td>
<td>10 (63)</td>
<td>-</td>
<td>6 (37)</td>
</tr>
<tr>
<td>Asystole, PEA*</td>
<td>5 (28)</td>
<td>2 (11)</td>
<td>11 (61)</td>
</tr>
</tbody>
</table>

*= First registered ECG rhythm. Values are reported as number of patients (%).
Paper II

One hundred and twenty-five CA patients treated with TH were included in the study. Demographic and medical characteristics and outcome data are presented in Table 5.

Table 5. Demographic and medical characteristics.

<table>
<thead>
<tr>
<th></th>
<th>All patients, n=125</th>
<th>Good outcome, n=57</th>
<th>Poor outcome, n=68</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>66 ±14 (18-85)</td>
<td>63 ±14 (23-85)</td>
<td>69 ±12 (18-85)</td>
<td>p=0.005</td>
</tr>
<tr>
<td><strong>Gender</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Male</td>
<td>83 (66)</td>
<td>38 (67)</td>
<td>45 (66)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>42 (34)</td>
<td>19 (33)</td>
<td>23 (34)</td>
<td></td>
</tr>
<tr>
<td><strong>OHCA</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td>108 (86)</td>
<td>52 (91)</td>
<td>56 (82)</td>
<td>NS</td>
</tr>
<tr>
<td>Witnesses</td>
<td>73 (58)</td>
<td>34 (60)</td>
<td>39 (57)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>First registered rhythm</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>p=0.009</td>
</tr>
<tr>
<td>VF/VT</td>
<td>57 (46)</td>
<td>35 (61)</td>
<td>22 (32)</td>
<td></td>
</tr>
<tr>
<td>Asystole</td>
<td>43 (34)</td>
<td>12 (21)</td>
<td>31 (46)</td>
<td></td>
</tr>
<tr>
<td>PEA</td>
<td>7 (6)</td>
<td>2 (4)</td>
<td>5 (7)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>18 (14)</td>
<td>8 (14)</td>
<td>10 (15)</td>
<td></td>
</tr>
<tr>
<td><strong>Angiography</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td>63 (50)</td>
<td>33 (58)</td>
<td>30 (44)</td>
<td>NS</td>
</tr>
<tr>
<td>PCI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>36 (30)</td>
<td>21 (37)</td>
<td>15 (22)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Minutes to ROSC</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22 ±15 (5-90)</td>
<td>20 ±14 (5-90)</td>
<td>24 ±15 (5-75)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Minutes from CA to</strong></td>
<td>360 ±185 (30-920)</td>
<td>367 ±189 (30-920)</td>
<td>354 ±182 (56-850)</td>
<td>NS</td>
</tr>
<tr>
<td>34°C&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Time spent in ICU days</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7 (1-93)</td>
<td>6 (2-23)</td>
<td>7 (1-93)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Medical history</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No previous illness</td>
<td>22 (18)</td>
<td>16 (28)</td>
<td>6 (9)</td>
<td>p=0.006</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>39 (31)</td>
<td>18 (32)</td>
<td>21 (31)</td>
<td>NS</td>
</tr>
<tr>
<td>Heart failure</td>
<td>30 (24)</td>
<td>14 (25)</td>
<td>16 (24)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension</td>
<td>62 (50)</td>
<td>24 (42)</td>
<td>38 (56)</td>
<td>NS</td>
</tr>
<tr>
<td>Lung disease</td>
<td>25 (20)</td>
<td>10 (18)</td>
<td>15 (22)</td>
<td>NS</td>
</tr>
<tr>
<td>Diabetes</td>
<td>29 (23)</td>
<td>7 (12)</td>
<td>22 (32)</td>
<td>p=0.007</td>
</tr>
<tr>
<td>Stroke</td>
<td>13 (10)</td>
<td>1 (2)</td>
<td>12 (18)</td>
<td>p=0.004</td>
</tr>
<tr>
<td>Malignancy</td>
<td>7 (6)</td>
<td>1 (2)</td>
<td>6 (9)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>CPC at 6 months</strong>&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPC 1</td>
<td>48 (38)</td>
<td>48 (84)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CPC 2</td>
<td>8 (6)</td>
<td>8 (14)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CPC 3</td>
<td>5 (4)</td>
<td>-</td>
<td>5 (7)</td>
<td></td>
</tr>
<tr>
<td>CPC 4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CPC 5</td>
<td>64 (51)</td>
<td>1 (2)</td>
<td>63 (93)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Mean ±SD (min-max)

<sup>b</sup>Number of patients (%)

A total of 841 blood samples were collected from 125 patients. There was small variation in the numbers of samples between the different biomarkers, and the main reasons were hemolysis or insufficient amount of serum to conduct the analysis. Six hundred and forty-five of the samples came from peripheral blood and 196 from jugular bulb. In 47 patients who were provided with a jugular bulb catheter, no differences were found in levels of GFAP,
NSE and S100B between peripheral and jugular bulb samples. The following results are from peripheral blood samples.

**GFAP**

There were differences between the good and poor outcome groups at 48 ($p=0.016$), 72 ($p=0.003$) and 96 ($p=0.018$) hours post-CA. High GFAP levels were more common in the poor outcome group. GFAP level at 0.83ng/mL was seen in one sample in the good outcome group, whereas the remaining samples had values $\leq$0.45ng/mL.

In the poor outcome group, GFAP levels above 0.83ng/mL were seen in 36 samples, ranging up to 445ng/mL. Of the patients with poor outcome, 18% (n=12) at 24 hours and 15% (n=10) at 48 hours had GFAP levels above 0.83ng/mL. The ROC analysis showed the highest AUC at 72 hours (Table 6). The sensitivity and specificity of specific cut-off values for predicting poor outcome are listed in Table 6.

**NSE**

There were differences between good and poor outcome at all sampling times ($p=<0.001$) except in the acute phase upon arrival to ICU. An NSE above 0.22 µg/L at 72 hours post-CA resulted in 100% specificity for a poor outcome with a sensitivity of 50%, and 96 hours post-CA a value above 18 µg/L resulted in 100% specificity with a sensitivity of 55% (Table 6).

**S100B**

Differences between good and poor outcome were significant at all sampling times ($p=<0.05$ and $p=<0.001$). The mean levels of S100B decreased in the good outcome group from the acute phase to 24 hours post-CA, but in the poor outcome group the mean levels instead increased between these time points. AUC value and sensitivity and specificity for S100B at different sampling times are presented in Table 6.
Table 6. Area under the curve (AUC) for poor outcome at different time points post-CA. Based on the coordinates, cut-off values with high specificity have been developed. Values calculated from peripheral blood samples.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Time after CA (hours)</th>
<th>Number of analysed samples</th>
<th>AUC (95% CI)</th>
<th>Cut-off value</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFAP</td>
<td>24</td>
<td>122</td>
<td>0.59 (0.50-0.70)</td>
<td>0.19 ng/mL</td>
<td>25</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.09 ng/mL</td>
<td>16</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>118</td>
<td>0.63 (0.53-0.73)</td>
<td>0.07 ng/mL</td>
<td>30</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.3 ng/mL</td>
<td>23</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>104</td>
<td>0.67 (0.56-0.78)</td>
<td>0.03 ng/mL</td>
<td>37</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.53 ng/mL</td>
<td>14</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>91</td>
<td>0.65 (0.53-0.76)</td>
<td>0.03 ng/mL</td>
<td>35</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.04 ng/mL</td>
<td>32</td>
<td>100</td>
</tr>
<tr>
<td>NSE</td>
<td>24</td>
<td>120</td>
<td>0.73 (0.65-0.82)</td>
<td>23 µg/L</td>
<td>36</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>49 µg/L</td>
<td>27</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>118</td>
<td>0.79 (0.71-0.87)</td>
<td>22 µg/L</td>
<td>48</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40 µg/L</td>
<td>37</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>101</td>
<td>0.85 (0.78-0.92)</td>
<td>18 µg/L</td>
<td>56</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22 µg/L</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>90</td>
<td>0.85 (0.77-0.93)</td>
<td>14 µg/L</td>
<td>62</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18 µg/L</td>
<td>55</td>
<td>100</td>
</tr>
<tr>
<td>S100B</td>
<td>24</td>
<td>120</td>
<td>0.78 (0.70-0.86)</td>
<td>0.24 µg/L</td>
<td>41</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.3 µg/L</td>
<td>23</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>118</td>
<td>0.75 (0.66-0.83)</td>
<td>0.2 µg/L</td>
<td>42</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.61 µg/L</td>
<td>21</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>101</td>
<td>0.83 (0.75-0.89)</td>
<td>0.18 µg/L</td>
<td>50</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.38 µg/L</td>
<td>30</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>90</td>
<td>0.80 (0.71-0.89)</td>
<td>0.14 µg/L</td>
<td>37</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.1 µg/L</td>
<td>3</td>
<td>100</td>
</tr>
</tbody>
</table>

Comparisons of biomarkers

Table 6 summarizes the results of ROC analysis for GFAP, NSE and S100B as neurological prognostic predictors. The AUC for NSE and S100B was higher than that for GFAP at all time points. Adding GFAP to a model containing NSE and S100B did not improve prediction of neurological outcome (Figure 5).
Figure 5. Logistic regression with stepwise combination of neuron-specific enolases (NSE), S100B and glial fibrillary acidic protein (GFAP) presented with receiver operating characteristic (ROC) analysis and area under the curve (AUC). Values calculated from peripheral blood samples.

Paper III

Twenty-six CA survivors treated with TH were able to answer the questionnaires at all three occasions and could therefore be included in the study. The mean age was 62 years and the sample consisted of more men (n=15, 58%) than women (n=11, 42%). Most of the participants lived with a partner (n=19, 73%). CA was in most cases witnessed (n=25, 96%), and the first registered ECG rhythm was most frequently VF/VT (n=20, 76%). When comparing data from the included survivors with the excluded group of survivors, who did not answer the questionnaires at all three occasions, there was a difference between the groups in first registered ECG rhythm (p=0.017), minutes to ROSC (p=0.009) and time spent in the ICU (p<0.001).

Outcome

An improvement in functional outcome was seen between ICU discharge and six months post-CA. See Table 7.
Table 7. *CPC score for the sample over time.*

<table>
<thead>
<tr>
<th>CPC</th>
<th>Discharge from ICU</th>
<th>M1</th>
<th>M2</th>
<th>M3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPC 1</td>
<td>8 (31)</td>
<td>21 (81)</td>
<td>24 (92)</td>
<td>26 (100)</td>
</tr>
<tr>
<td>CPC 2</td>
<td>16 (62)</td>
<td>5 (19)</td>
<td>2 (8)</td>
<td>-</td>
</tr>
<tr>
<td>CPC 3</td>
<td>2 (8)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CPC 4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CPC 5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Number of patients (%)

The participants’ working situation changed over time and is presented in Table 8.

Table 8. *Working situation for participants over time.*

<table>
<thead>
<tr>
<th>At the time of the CA</th>
<th>M2</th>
<th>M3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worked full time</td>
<td>6 (23)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>Worked part time</td>
<td>4 (15)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>Sick leave</td>
<td>-</td>
<td>8 (31)</td>
</tr>
<tr>
<td>Retired</td>
<td>16 (62)</td>
<td>16 (62)</td>
</tr>
</tbody>
</table>

Number of patients (%)

Changes over time in anxiety, depression and HRQoL

Changes over time in self-reported anxiety, depression and HRQoL are presented in Figure 6. The participants showed improvement over time in HRQoL, but not in anxiety and depression.
Figure 6. Levels of self-reported HRQoL, anxiety and depression, presented with mean. Changes over time (M1-M2-M3) using Friedman’s calculation.

Correlation between anxiety and depression and HRQoL

The correlation between the HADS subscales, anxiety and depression, and the two SF12 components and the EQ5D index was investigated. One month post-CA (M2), correlations are observed between SF12 MCS and both of the HADS subscales anxiety ($r_s = -.70, p \leq 0.001$) and depression ($r_s = -.65, p \leq 0.001$).
The strongest correlations are observed at six months post-CA (M3) between the HADS subscale depression and SF12 PCS and shows, the more depression the less HRQoL as shown in Figure 7.

*Figure 7. Correlation at M3 between HADS depression and HRQoL SF12 PCS (r = -0.70, p ≤ 0.001)*
Descriptive distributions of the questionnaires

Table 9 shows the distributions of the questionnaire responses.

Table 9. Reported level of anxiety, depression and HRQoL. n=26.

<table>
<thead>
<tr>
<th></th>
<th>M1</th>
<th>M2</th>
<th>M3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HADS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety 0-7</td>
<td>21 (8)</td>
<td>19 (74)</td>
<td>22 (84)</td>
</tr>
<tr>
<td>Anxiety 8-10</td>
<td>4 (15)</td>
<td>4 (15)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Anxiety ≥11</td>
<td>1 (4)</td>
<td>3 (11)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>Depression 0-7</td>
<td>21 (81)</td>
<td>20 (77)</td>
<td>23 (89)</td>
</tr>
<tr>
<td>Depression 8-10</td>
<td>2 (8)</td>
<td>3 (11)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>Depression ≥11</td>
<td>3 (11)</td>
<td>3 (11)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>EQ-VAS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90-100%</td>
<td>0 (0)</td>
<td>1 (4)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>80-89%</td>
<td>5 (19)</td>
<td>10 (38)</td>
<td>10 (38)</td>
</tr>
<tr>
<td>70-79%</td>
<td>2 (8)</td>
<td>2 (8)</td>
<td>2 (8)</td>
</tr>
<tr>
<td>60-69%</td>
<td>6 (23)</td>
<td>1 (4)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>50-59%</td>
<td>8 (31)</td>
<td>3 (11)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>&lt; 50%</td>
<td>5 (19)</td>
<td>8 (31)</td>
<td>5 (19)</td>
</tr>
<tr>
<td>Missing value</td>
<td>1 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EQ5D</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>12 (46)</td>
<td>17 (65)</td>
<td>18 (69)</td>
</tr>
<tr>
<td>Problems</td>
<td>14 (54)</td>
<td>9 (35)</td>
<td>8 (31)</td>
</tr>
<tr>
<td>Self-care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>20 (77)</td>
<td>23 (88)</td>
<td>25 (96)</td>
</tr>
<tr>
<td>Problems</td>
<td>6 (23)</td>
<td>3 (12)</td>
<td>1 (4)</td>
</tr>
<tr>
<td>Usual activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>11 (42)</td>
<td>15 (58)</td>
<td>21 (81)</td>
</tr>
<tr>
<td>Problems</td>
<td>15 (58)</td>
<td>11 (42)</td>
<td>5 (19)</td>
</tr>
<tr>
<td>Pain/Discomfort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>5 (19)</td>
<td>11 (42)</td>
<td>13 (50)</td>
</tr>
<tr>
<td>Problems</td>
<td>21 (81)</td>
<td>15 (58)</td>
<td>13 (50)</td>
</tr>
<tr>
<td>Anxiety/depression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>11 (42)</td>
<td>15 (58)</td>
<td>16 (62)</td>
</tr>
<tr>
<td>Problems</td>
<td>15 (58)</td>
<td>11 (42)</td>
<td>10 (38)</td>
</tr>
<tr>
<td><strong>SF12</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCS ≥40</td>
<td>17 (65)</td>
<td>19 (73)</td>
<td>23 (89)</td>
</tr>
<tr>
<td>MCS &lt;40</td>
<td>8 (31)</td>
<td>7 (27)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>Missing value</td>
<td>1 (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCS ≥40</td>
<td>7 (27)</td>
<td>7 (27)</td>
<td>16 (62)</td>
</tr>
<tr>
<td>PCS &lt;40</td>
<td>18 (69)</td>
<td>19 (73)</td>
<td>10 (38)</td>
</tr>
<tr>
<td>Missing value</td>
<td>1 (4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Number of patients (%)
Paper IV

Participants in the study underlying Paper IV are henceforth described as relatives and the person who had suffered the CA as the next of kin. The analysis revealed in ten categories and three themes through which the relatives described their experiences the first time after the next of kin’s CA. See Table 10.

Table 10. Overview of categories and themes.

<table>
<thead>
<tr>
<th>Categories</th>
<th>Themes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difficulties taking in what had happened</td>
<td>The first period of chaos</td>
</tr>
<tr>
<td>Feeling fear</td>
<td></td>
</tr>
<tr>
<td>Waiting in uncertainty</td>
<td></td>
</tr>
<tr>
<td>Painful to see a relative seriously ill</td>
<td></td>
</tr>
<tr>
<td>Receiving support</td>
<td>Feeling secure in a difficult situation</td>
</tr>
<tr>
<td>Receiving information</td>
<td></td>
</tr>
<tr>
<td>Feeling variations in the quality of care</td>
<td></td>
</tr>
<tr>
<td>Feeling increased demands and responsibility</td>
<td>Living in a changed existence</td>
</tr>
<tr>
<td>Concerns for the future</td>
<td></td>
</tr>
<tr>
<td>The next of kin has changed</td>
<td></td>
</tr>
</tbody>
</table>

The first period of chaos

This theme describes how the relatives experienced the acute phase after their next of kin had suffered the CA. They described a sense of unreality for what had happened and a chaotic and shattering experience but with rational thoughts. The CA caused feelings of fear, panic and anxiety. The relatives found it difficult to see their next of kin seriously ill. They described the TH as unpleasant and the next of kin felt cold and almost dead. The time before the next of kin woke up was stressful because of the uncertainty as to whether he/she had suffered any injuries, and if so, what kind.

Feeling secure in a difficult situation

This theme illuminates the relatives’ need for support and information as well as the variations in the care their next of kin received. The relatives experienced the support from their family as the most important form of support. All of the relatives received information about their next of kin’s condition, but experienced difficulties in assimilating the information because it was hard for them to concentrate. They wished there had been more written information about what caused the CA, the prognosis and information about prevention.

The relatives experienced the care in the ICU as good and safe. The personnel behaved professionally and competently: they were kind and en-
gaged, treating all family members with consideration, but the need for a routine for how to taking care of relatives was emphasized. At the general ward, the relatives felt the staff were less supportive and engaged than staff at the ICU. The possibility to receive rehabilitation and care after hospital discharge was insufficient.

Living in a changed existence

The impact on everyday life after their next of kin’s CA is illustrated in this theme. The relatives experienced increased workload and a responsibility to support other family members. They described a demand for keeping a continuous contact with other family members and friends by phone calls, but felt they spent too much time by the phone. These feelings gave them a bad conscience. They felt responsible for their next of kin and wanted to support them to the outmost. The relatives felt great uncertainty and anxiety about the future. They were worried about their next of kin’s physical changes, but also hopeful and wished to see the future with confidence. They felt they had been changed by the incident, and thoughts about death and the meaning of life were common. The next of kin was still affected by the CA, experiencing problems with his/her short-term memory, speech, balance and walking as well as physical and mental complications.
Discussion

This work focused on CA patients who reached the ICU and the overall aim of this thesis was to study post-resuscitation care with focus on therapeutic hypothermia, outcome up to six months and relatives’ experiences. The findings showed that cold intravenous infusion combined with ice packs was useful with close monitoring of the body temperature in inducing and maintaining TH and also controlling rewarming. In Paper II we found that GFAP was significantly increased in the poor outcome group post-CA but NSE and S100B were shown to be better in predicting neurological outcome. HRQoL improved over time over the first six months post-CA. There were also relatively high negative correlations between anxiety, depression and HRQoL six months post-CA. The relatives described their experiences during the acute phase as a time of chaos. They found it difficult to assimilate the medical information and wanted it in written form, and the information should be clear and honest. They lacked rehabilitation plans, felt uncertain about the future, but still hopeful.

Therapeutic hypothermia

Therapeutic hypothermia for survivors of OHCA has been shown to improve both survival and long-term neurologic outcomes\textsuperscript{30,31} and has been endorsed by American and European guidelines\textsuperscript{7,12} However, the optimal approach to providing TH is a topic of ongoing research. For example, a recent large trial demonstrated that targeting a temperature of 36°C provides similar results to a temperature goal of 33°C.\textsuperscript{16} In Paper I, we evaluated a method for TH with cold saline infusion combined with ice packs. All patients reached the target temperature of 32-34°C on average 4.4 hours from cardiac arrest and 3.4 hours from induction of TH. These results are in line with other studies.\textsuperscript{10,30,31,41,45,54,55,58,168} When making a retrospective comparison between the studied population and the patients for whom the same cooling method was used as for the participants from Paper II, the time to target temperature tended to increase (Table 11). There is no explanation for the increased time to target temperature: there was no difference in number of angiographies or PCIs between the groups, and the observations were performed at the same unit using the same guidelines. Given the personnel’s longer experience of using the method, it is sur-
prising that the time increased. When Study I was underway, it was known among the personnel that the cooling method was being evaluated, which may have affected the results. However, a fast time to target temperature has not been shown to be associated with better outcomes.\textsuperscript{44, 168, 169} Time for rewarming increased between the two periods but might be explained by the different target of normal temperature, 36°C versus 36.5°C.

Table 11. Comparison between Paper I and patients cooled with the same method during the second inclusion period.

<table>
<thead>
<tr>
<th></th>
<th>n=38, 2004-2007</th>
<th>n=75, 2008-2012</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from CA to target temp\textsuperscript{a}</td>
<td>279 minutes ±185 (60-650)</td>
<td>342 minutes ±181 (30-920)</td>
<td>0.06</td>
</tr>
<tr>
<td>Time from cooling start to target temp\textsuperscript{a}</td>
<td>216 minutes ±177 (10-570)</td>
<td>274 minutes ±178 (0-865)</td>
<td>0.07</td>
</tr>
<tr>
<td>Time for rewarming\textsuperscript{a}</td>
<td>8.2 hours* ±3.2 (1.2-16.5, n=36)</td>
<td>14.9 hours** ±6.1 (5.0-36.5, n=74)</td>
<td>0.00</td>
</tr>
<tr>
<td>Angiography\textsuperscript{b}</td>
<td>19 (50)</td>
<td>33 (44)</td>
<td>0.54</td>
</tr>
<tr>
<td>PCI\textsuperscript{b}</td>
<td>13 (34)</td>
<td>17 (23)</td>
<td>0.19</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Mean ±SD (min-max)
\textsuperscript{b}Number of patients (%)
* Started 26 hours after CA until patient reached 36°C
** Started 26 hours after CA until patient reached 36.5°C

In this study, the temperature remained stable during the maintenance phase. Cooling below the temperature range did occur but was not a major problem. In nine patients (24%), the temperature dropped below 32°C, and the lowest temperature, 31.3°C was noted in one patient. Problems with keeping the temperature stable have been reported when using ice packs as a cooling method, and temperatures below 32°C occurred in 10-63% of the patients.\textsuperscript{37, 170} In the current study, the temperature was monitored every 15 minutes and early information about changes in body temperature was obtained, which might have been a reason for the relatively stable temperature. We therefore consider that careful monitoring of body temperature during treatment is necessary to achieve good temperature control with the present method. For detection of changes in body temperature, the recommendation is to register the core temperature.\textsuperscript{7} In this study, bladder temperature measurement was used. It has been reported that the most accurate way to measure core temperature is in a central vein, which resulting in small variance even during the cooling phase.\textsuperscript{171}

Rewarming can be performed using the same devise that is used for cooling. With the method used in the present study, careful monitoring of temperature was required in order to control the rate of temperature elevation. Additional sedation was given or ice packs re-applied in an effort to prevent too rapid rate of rewarming. The recommendation is to rewarm the patients after TH at a maximal rate of 0.2–0.5°C/h.\textsuperscript{12, 13} Rewarming in the present study continued for 8.2 hours, and was comparable to times reported from
other studies. A high rewarming rate (>0.5°C/hour) has not been found to be associated with a higher risk for poor outcomes.

Rebound hyperthermia (>38°C) has been registered in about one fifth of patients, and was also seen in the present study. In the group of patients with rebound hyperthermia (n=8), four had good outcome and four poor outcome six months post-CA. In other studies, post-hypothermia fever occurred in half of the patients, and did not show any relation to outcome at hospital discharge or after six months. In another study, post-hypothermia fever was associated with mortality one month post-CA.

There are several different cooling devices available on the market and all have their strengths and weaknesses. The method applied in this study could be initiated early and did not interfere with other interventions, which most frequently consisted of an immediate transfer from the emergency ward for coronary angiography or CT scan of the brain. Each unit should choose a cooling device that suits it logistically, and the personnel should be trained to use it.

Prognostication

Predicting neurological outcome after CA is an important aspect of patient care and the information given to relatives. Early prognostication is difficult, as treatment with TH and sedation influences several of the prognostic tools. Biomarkers are likely to be independent of the effect of sedative drugs, but whether or not TH affects the levels of biomarkers is unclear, and TH may influence the time course of biomarkers. For prediction of neurological outcome based on biomarkers, it is important to have a method with high specificity.

In Paper II, GFAP, a relatively new biomarker in the field of CA, was evaluated as a neurological predictor, together with the more commonly studied biomarkers NSE and S100B. The result showed that GFAP was significantly increased in the poor outcome group at 48, 72 and 96 hours post-CA. However, NSE and S100B were shown to be better in predicting neurological outcome.

In the poor outcome group, GFAP was increased, but not in all patients. We could not find any explanation why some in the poor outcome group had increased levels, while others were normal. Levels above 0.83ng/mL were only seen in the poor outcome group and were most frequently occurring at 24 and 48 hours post-CA. In contrast to the good outcome group, where only slightly elevated levels of GFAP were seen. Similar results have also been observed in previous studies on CA patients. In the present study, GFAP predicted poor neurological outcome with 100% specificity and 14-32% sensitivity at 24, 48, 72 and 96 hours post-CA. An earlier study on 12 CA patients treated with TH reported sensitivity between 37-75% for GFAP.
at different time points when specificity was set to 100%. One problem with comparing biomarkers from different studies is the lack of standardization and the difference between assays and laboratories.

It has been difficult to found a reliable cut-off value for biomarkers. To predict poor neurological outcome using NSE, the best threshold in the present study was 18 µg/L 96 hours post-CA with specificity at 100% and sensitivity at 55% (Table 6). This seems to be a lower cut-off value than previously described. S100B values of 0.18 and 0.21 µg/L have been reported as cut-off values 24 hours post-CA with specificity at 100%. The corresponding value in the present study was 1.3 µg/L 24 hours post-CA with 100% specificity which is substantially higher (Table 6). In the present study, for GFAP levels to predict neurological outcome with 100% specificity, a cut-off value of 0.04 ng/ml 96 hours post-CA was found to be appropriate (Table 6). It should be noted, however, that because no certified reference material for assay calibration exists, it is difficult to compare values obtained using different methods. The present method has not previously been used in CA patients.

In patients with traumatic brain injury, increased levels of GFAP have been reported. One study used a cut-off level of 1.5 µg/L with specificity at 95% and sensitivity at 53% for predicting poor outcome, which is a considerably higher cut-off level than was found with 100% specificity in the present study. In stroke patients, the level of GFAP has been shown to correlate with the severity of brain damage and infarct volume. In a meta-analysis of the usefulness of GFAP as a marker after acute stroke, it was found that GFAP is effective to use in differential diagnosis. Specificity has varied between 70-98%, but different cut-off levels have been reported.

In the study presented in Paper II, a logistic regression analysis was performed for stepwise combinations of NSE, S100B and GFAP. A combination of current biomarkers did not increase the ability to predict neurological outcome. For prognostication, continuous evaluation of the patient’s prognosis is needed and a combination of predictors is recommended.

To our knowledge, biomarkers in the jugular bulb have not been studied in CA patients. In theory we had expected higher levels of biomarkers in the samples from the jugular bulb, given the direct drainage of blood from the brain. However, in the present study, levels of GFAP, NSE and S100B in peripheral blood and the jugular bulb did not differ.

Outcome

In Paper I-III, the patients’ neurological outcomes have been evaluated using the CPC scale. About forty-five percent of the patients in both Paper I and II had scored a good outcome (CPC 1-2) after six months. There was clinical
improvement over time from ICU discharge to six months. After the introduction of TH, several studies have reported outcome data comparable with our findings.\textsuperscript{10, 16, 40, 41, 44, 135, 177} In Paper III, the participants improved their CPC scores over the six months the study continued and all achieved CPC 1 after six months. In long-term follow-up after CA, the majority of patients who regained consciousness do well according to the CPC scale, but the scale is a rather crude measure, which makes it difficult to detect changes in HRQoL, cognitive function, anxiety and depression.\textsuperscript{115, 131, 135} It is recommended that evaluation after CA also include HRQoL.\textsuperscript{8} Even if the patients included in Paper III achieved a CPC score indicating they had recovered, they reported that their HRQoL was affected, and physical problems were more common than mental problems. In tradition, the CPC scale has been used for evaluating outcome in CA patients.\textsuperscript{4, 5} A similar scale is the modified Rankin scale (mRS), a 7-point scale ranges from 0 to 6, which is described more directed towards global disability and more focused on functional domains.\textsuperscript{178} mRS was first developed for stroke patients,\textsuperscript{178} but has also been used on CA patients and compared to the CPC scale and the two scales were found to have a comparable relationship to measure outcome.\textsuperscript{179} Another study found an overestimation of outcome in 15% of the patients using CPC at hospital discharge compared to follow-up 6-12 months post-CA using mRS.\textsuperscript{180}

In Paper III, there was a significant change over time showing increased levels of self-reported HRQoL using the EQ5D index and the SF12. Before TH was used in the treatment of CA patients, HRQoL was shown to improve during the first year post-CA.\textsuperscript{181} This indicates that patients who suffer a CA require time to recover, and that their HRQoL does improve over time. That patients need time for recovery also emphasizes by Fugate and Rabinstein in a recently published editorial.\textsuperscript{182} Earlier studies have not found any significant differences in HRQoL measured between 6-36 months after CA compared with the normal population.\textsuperscript{127, 129-131, 183} The present findings using the SF12 show that the level of HRQoL did not reach the level in a Swedish population for PCS, but did reach almost the population level for MCS after six months.\textsuperscript{161} HRQoL measured using the EQ5D index six months post-CA almost reached the level in a Swedish population.\textsuperscript{184} This is still in line with previous follow-up studies six months after CA in which HRQoL was slightly poorer (n.s.) though still fairly good compared to the normal population.\textsuperscript{130, 183} Using EQ-VAS to estimate overall health status, 41% of the participants in the present study scored below 70 six months post-CA. In an earlier study on CA patients with similar characteristics, 25% scored below 70 7.2 months post-CA.\textsuperscript{135} Looking at the present participants’ medical history, we see that 63% had some illness prior to the CA, which may have influenced their ratings of HRQoL and overall health status. Participants medical history is not presented in the comparative study.\textsuperscript{135} Overall this indicates that persons who have suffered and survived a CA generally esti-
mate their HRQoL as good. Life satisfaction and QoL are concepts that are
closely to each other. In one study, most of the CA patients reported their
satisfaction with “life as whole” to be good.\textsuperscript{134}

In the study, presented in Paper III, the strongest correlations were shown
between depression and HRQoL after six months, but correlations were also
seen between both anxiety and depression and HRQoL at hospital discharge,
after one month and after six months. Moulaert et al. found a correlation
between anxiety and depression and HRQoL 36 months after CA when using
the SF36 questionnaire.\textsuperscript{127} The present results and those of Moulaert et al.
show a similar correlation, which remains a long time after the CA. The
negative correlation between HRQoL and anxiety and depression shows that
it is important to screen for and identify anxiety and depression problems to
help patients to recover and be able to achieve a good QoL.\textsuperscript{182} In the present
study, signs of anxiety and depression measured using HADS showed no
significant changes over time. Nevertheless, the number of patients who
scored high on anxiety disorders tended to increase at one month post-CA,
before decreasing at six months. The measurement at one month was per-
formed close in time after hospital discharge, which may have negatively
affected the patients and caused more feeling of anxiety. This might be ex-
plained by increased fatigue, loss of security at not having medical staff
nearby and insight into what has happened to them. None of the participants
had a previous history of anxiety or depression documented in their medical
journal. In a recently published study, an intervention with consultations by a
trained nurse was conducted to detect early emotional problems after CA,
and both the patients and their caregivers positively evaluated the interve-
nion.\textsuperscript{185} This demonstrates the importance of strategies for identifying and
treating emotional problems such as anxiety and depression. The study pre-
sented in Paper III was conducted in a small population with inclusion crite-
rria excluding CA patients who needed a hospitalization up to one month or
longer. This might have resulted in a selected group of patients, but in any
case, patients had an influence on HRQoL and anxiety and depression.

The participants in Paper III had a higher frequency of VT/VF and fewer
asystoli as the first registered ECG rhythm compared to the excluded group
during the study period. This might have influenced the study results, as
these factors are known to be associated with survival and morbidity.\textsuperscript{186} In
Paper I, we also found a higher proportion of good outcomes in the VF/VT
group.

A large number of different questionnaires have been used in studies to
measure HRQoL after CA, and the time to follow-up varies.\textsuperscript{115, 117} This
makes it difficult to compare findings between different studies.
Relative’s experiences

The findings in Paper IV show that relatives of a person who has suffered a CA desired more information, especially written, on the cause of the CA, treatment, prognosis and prevention. Keeping contact with other family members and friends was described as demanding and the absence of a rehabilitation plan after discharge from the medical ward was also a major issue.

One of the most important needs for the relatives of ICU patients is information that is clear and honest.148, 149, 155, 187 In the present study, relatives wanted honest and clear information about their next of kin’s condition and prognosis. The relatives also found it difficult to assimilate the information provided. This has been confirmed in other studies.137, 150, 188 It appears that relatives cannot interpret and absorb the information given, and thus the information should be presented on several occasions.136, 148, 189, 190 Holm et al. found that partners of CA survivors were not prepared for the challenges that would arise when the next of kin was discharge from hospital.150 To reduce relatives’ anxiety and burden, it is important that they are informed and prepared, and that there is a plan for how continued care will be performed. The participants in Paper IV described the absence of a rehabilitation plan after discharge from the medical ward. Relatives felt uncertain about the future, but hopeful. It was important for them to feel hope even when the situation was critical and the prognosis uncertain. Studies have revealed the importance of hope when a next of kin is critically ill and shown that hope is of greater importance in cases of unexpected incidences than in chronically evolving illness.137, 138, 146, 148, 149 Relatives’ need for hope must be taken into account when staff meet with them. Because relatives desire honest and realistic information, it is important that staff encourage hopefulness without promoting unrealistic hope. Relatives experience ambivalence, that is they are caught between wanting honest information and needing to remain hopeful.191, 192 The feeling of hope is complex, and hope has several dimensions. Even in moments of hopelessness, hope might suddenly appear.193 Hope has been described as a way to cope with the situation when a close relative becomes critically ill.191, 192 In the present study, all relatives experienced support and the most important support came from other family members. Another study found that relatives prefer to talk to someone they know rather than to a hospital social worker or a priest.137 Having a social network has also been described as a way to cope with the situation.194

One surprising result was the demand placed on relatives to maintain telephone contact with other family members and friends. This was time consuming and instead they would have preferred to have time to relax and think. These feelings resulted in guilt and a bad conscience. Holm et al. described the demands as a burden, in that other family members and friends took time from the next of kin.150 Increased responsibility became apparent
in the form of supporting other family members and dealing with others’ worries, while being concerned about their next of kin. Concern for other family members has been described as a double worry in relation to how they will handle the situation. Six months after the next of kin’s CA, relatives still have reported increased demands, both in relation to the next of kin and other family members.

In the present study, relatives described difficulties in understanding and absorbing what had happened, and the situation felt unreal. They protected themselves from unpleasant memories. Uncertainty was prevalent among relatives during the acute phase, and waiting in uncertainty was described as a time filled with anxiety and fear. The next of kin’s illness and thoughts about what kind of injuries the next of kin had suffered were powerful causes of stress. High levels of traumatic stress, anxiety and depression are described in relatives during the first days after a next of kin’s admission to an ICU. This should be kept in mind in the care of relatives to CA patients.

Intensive care is a highly technological ward, capable of providing advanced treatment and nursing care for critically ill people. The care in the general ward is more focused on supporting, the monitoring is less important and staffing levels are lower. In the present study, relatives described a difference between the ICU and the general ward in terms of effective interpersonal relations, attitudes, and knowledge on the part of staff as well as lack of contact with staff. In line with this findings, ICU nurses and nurses in general ward have described a gap in care and differences in the environment, differences in the nurses’ competence and in how to communicate. Transfer from the ICU to a general ward has been described as stressful and an issue that causes anxiety for patients and family members. Experiences depend on how the relatives and patients are treated by the staff and the information received before, during and after transfer from an ICU to the general ward.

Methodological considerations

This thesis includes both quantitative and qualitative research designs. The research question and feasibility of data collection determined the choice of design. The advantage of using both quantitative and qualitative research designs is that the methods reinforce each other and different research questions can be answered and a wider area investigated. This thesis also include different perspectives; medical care (Paper I and II), patients (Paper III) and relatives (Paper IV).
Paper I
As our purpose was to describe a method of cooling, we employed a descriptive design. The study was intended for clinicians, treating CA patients with TH, to provide knowledge about the described cooling method used in the ICU. This was an observational study that did not involve comparisons with a normal-temperature control group or other established cooling devices. Not having any control group is a limitation, but because the purpose was to describe rather than to compare, the design was preferable. The available patients during the study period were consecutively included. The small sample size precluded any major assessment of the effect of this technique on the outcome and makes the results difficult to generalize. Five patients were excluded because the temperature protocol was not completed, and this may have biased our results.

Paper II
The design used in Paper II was a prospective observational study. The patients available during the study period were consecutively included. As the study had an exploratory purpose, no power calculation was performed. In the study, some data are missing due to hemolysis or insufficient amounts of serum to conduct the analysis, which could have affected the results. It is difficult to compare results across different studies due to the use of different assays for analysing biomarkers, which is a limitation in the area of biomarkers as regards finding reliable cut-off levels. Results on the biomarkers were not available to the caregivers and therefore could not have affected treatment or evaluation of the patient, which should be seen as a strength in the study.

Parts of the results are presented with sensitivity and specificity. Sensitivity is the ability to identify a condition correctly, in this study to identify patients with a possibility of achieving a good outcome. Specificity is the ability to identify non-cases correctly, thus in the present study to identify those with a poor outcome. In the present study, we pursued high specificity to avoid diagnosing poor outcome in patients with a possibility to recover, i.e. a low FPR. The accuracy of the test depends on how well the tests separate the good and poor outcome groups and is measured by AUC. The larger the area, the more accurate the test.

Paper III
This study prospectively investigated changes over time in HRQoL, anxiety and depression. Important strengths of the study are that all participants were followed up at the same time intervals from CA at M2 and M3, and followed over time. A limitation is the variation in hospital stay post-CA, which affected time from CA to M1 (min 1.0, max 3.5 weeks), resulting in a time from M1 to M2 of 1 week in 3 cases. The small study population is a limita-
tion that might have affected the results. Inclusion required participants to complete the questionnaires at three occasions, and thus they needed to have been discharged from hospital within one month after CA. This only applied to about half of the patients who survived CA and may have resulted in a selected group of CA patients.

All of the standardized questionnaires used in the study have been tested for validity and reliability. For two of the questionnaires, there are normative data available for the general Swedish population (SF12, EQ5D). The questionnaires all involve self-reporting. Any cognitive impairment resulting from CA and also the risk of trying to please the investigators may have influenced participants’ answers.

Because multiple statistical tests were performed on the same data for comparison and correlation, a higher level of significance was used ($p$-value ≤ 0.01; two-tailed). This may have increased the risk of type II error, a false negative conclusion entailing failure to detect differences when they really exist.

The reliability of the questionnaires was expressed as a Cronbach’s $\alpha$ coefficient. Cronbach’s $\alpha$ is used to test the reliability of an instrument and to ensure that all items in a test measure the same phenomenon. Cronbach’s $\alpha$ is a method of evaluating internal consistency. There is no standard for what an acceptable Cronbach’s $\alpha$ coefficient should be, but values ranging from 0.70-0.90 have been reported.$^{163,199}$ Low levels were seen at M1 and M3 in EQ5D, probably owing to the small number of items.

**Paper IV**

The methodological approach in Paper IV was qualitative description and was influenced by Sandelowski’s work. Qualitative description is a method used for classification of experiences and to answer questions such as “who, what and where”.$^{200,201}$ Qualitative content analysis seemed an appropriate method, as our intention was to describe relatives’ experiences, with a focus on similarities and differences narrated in the interviews. An inductive approach was used.$^{163,164}$

Trustworthiness is important in qualitative studies, and according to Graneheim and Lundman it comprises credibility, transferability and dependability.$^{164}$ To achieve trustworthiness several aspects were considered during the process.

Credibility refers to confidence in the truth of the data and how well the data and processes of analysis describe the study area.$^{163,164}$ To achieve credibility, participant selection aimed at variation in demographic characteristics, and a pilot interview was performed to test the interview guide and examine whether the three researchers were focusing on the same topics. The interviews took place at about the same time after the next of kin’s CA, which made the participating relatives’ experiences comparable in this respect. The interviewers were familiar with the research field, and their pre-
understanding of the context may have contributed to trust and understanding among the relatives during the interviews as well as been helpful when analysing the data. Their pre-understanding could also be a weakness as it might have influenced the following-up questions, i.e., if the interviewer takes a given statement for granted. Limitations of this study are that only those who could understand and speak Swedish were included in the study. Because of the distance involved four of the interviews were conducted over telephone. According to Novick, face-to-face interviews are to preferable because the lack of visual cues during telephone interviews could lead to data loss or distortion. In the present study, the telephone interviews had a lighter and more limited content. However, this was compensated by the face-to-face interviews, which were more complex and exhaustive.

Dependability refers to the stability of data over time and condition, as well as how well the research process and analysis can be followed. To enhance dependability an interview guide was used. During the analysis the authors continuously discussed the steps in the process. The last author is experienced in the method used in Paper IV and supervised the other authors involved in data collection and analysis.

Transferability describes to what extent the findings can be transferred to other settings and groups. By offering a sufficient description of participants and including participants that varied in terms of age, sex and relationship, transferability from the present study has been facilitated. Given the method used, the present results cannot be generalized, but they can be transferred to relatives in a similar situation.
Conclusions

This thesis focused on the care of CA survivors and their relatives. The results have helped to improve the knowledge in the areas studied. The results from the studies present aspects that should be taken into account in the overall treatment of this group of patients, and they show the importance of developing an overall view and of having a chain of care from an individual’s CA until follow-up for both the patient and his/her relatives.

- Use of cold intravenous saline infusion (4°C) together with ice packs placed in the groins, axillae and along the neck is a method for inducing and maintaining therapeutic hypothermia after CA that offers good temperature control even during the rewarming phase (I).
- GFAP in serum was increased in patients with poor outcome but did not show sufficient sensitivity for predicting neurological outcome after CA. Both NSE and S100B were more sensitive assessments in this area (II).
- A combination of NSE, S100B and GFAP did not increase the ability to predict neurological outcome (II).
- No differences were seen in levels of GFAP, NSE and S100B between peripheral and jugular bulb blood samples (II).
- Self-reported HRQoL after CA improved over the first six months. Patients reported lower levels of HRQoL on the physical as compared to mental component (III).
- The less anxiety and depression patients perceive, the better HRQoL they have; time can be an important factor in recovery after CA (III).
- This group of relatives desired more information, especially written, on the cause of the CA, treatment, prognosis and prevention (IV).
- Maintaining contact with other family members and friends was described as demanding (IV).
- Relatives of a person who has suffered a CA described the absence of a rehabilitation plan for their next of kin (IV).
Clinical implications and future perspectives

This research began in my clinical practice in the ICU, caring for CA patients and their relatives. Some suggestions for clinical practice, based on the findings in the thesis, have emerged.

• The cooling method presented in Paper I is feasible in clinical practice at low cost and should be considered as an alternative to other methods of planned hypothermia treatment.

• Routinely collecting jugular bulb samples for analysing biomarkers is not recommended based on the results in Paper II.

• Screening for anxiety, depression and HRQoL should be provided to identify those who are in need of additional support.

• Information about available support and booklets describing CA, the ICU stay and continuing care and rehabilitation directed at both the patients and their relatives are needed. Current booklets used in the ICU need to be more developed and detailed. Follow-up visits for both patients and relatives need to be considered.

• ICU staff must support relatives and encourage relatives to designate a contact person who can forward information to other family members and friends.

• Relatives and patients need to be prepared for the change in level of care and environment in the general ward before moving from the ICU.

• Hospitals should consider establishing a rehabilitation plan for this group of patients that is presented by a multidisciplinary team of healthcare professionals and that focuses on the individual’s situation, including the consequences of his/her heart disease and brain damage.

In a future perspective, additional knowledge about the care for CA patients and their relatives is needed. Because CA patients are a heterogeneous group with both heart and brain disease as well as different co-morbidities it might be difficult to get clear answers to the questions raised, and for this reason more research is needed. Here are some suggestions based on this thesis.

• The cooling method, presented in Paper I, needs to be evaluated at different target temperatures.

• Further evaluations of different prognostic tools are needed for accurate and early prognostication after CA and TH. The role for biomarkers needs more evaluation, including the development of standardized assessments and reliable cut-off levels.
• An instrument for identifying and screening CA survivors is needed for physical and psychological follow-up.
• A follow-up study is recommended to further investigate relatives’ quality of life and posttraumatic stress.
Antalet personer som överlever ett hjärtstopp har ökat det senaste årtiondet vilket innebär att även ökad kunskap behövs om hur vården av hjärtstoppsoverlevare och deras närstående ska förbättras. Personer som återfår bärande cirkulation efter ett hjärtstopp är en patientgrupp med komplex sjukdomsbild vilket är en utmaning i vården av patienterna, både i den akuta fasen på intensivvårdsavdelningen och den fortsatta vården och rehabiliteringen.

Avhandlingens syfte var att undersöka vården av patienter som överlevt ett hjärtstopp med fokus på en metod för kylbehandling, bedömning av prognos med användning av hjärnskademarkörer, hur patienterna skattar sin livskvalitet under de första sex månaderna och hur närstående upplever den första tiden efter hjärtstoppet.

Delarbete I

Delarbete II
Prognostifiering och bedömning av neurologiskt utfall efter ett hjärtstopp med ischemisk hjärnskada är en utmaning för behandlande personal. I delarbete II har hjärnskademarkören glial fibrillary acidic protein (GFAP) undersöks som prognostiskt verktyg för att bedöma patienternas neurologiska utfall. Den har även jämförts med de mer dokumenterade hjärnskademarkörerna neuron-specific enolases (NSE) och S100B. Resultatet visade att nivån av GFAP var högre hos de patienter som hade ett dåligt neurologiskt utfall jämfört med de som hade ett bra. Det gick däremot inte att visa att GFAP hade tillräckligt hög känslighet för att bedöma neurologiskt utfall efter hjärtstopp. Både NSE och S100B var känsligare för bedömning av neurologiskt utfall.
**Delarbete III**


**Delarbete IV**

Acknowledgements

I would like to express my gratitude to every person who has contributed directly or indirectly to this thesis. Without your knowledge, support, and encouragement, I would not have been able to complete it. I especially want to thank:

All patients and their relatives in the studies for giving me your time and sharing your experiences.

Sten Rubertsson, my supervisor, for introducing me to scientific work, for your insightful comments, for entering new areas with enthusiasm and for having the courage to choose a nurse as PhD student.

Marja-Leena Kristofferzon, my co-supervisor, for your encouragement and support throughout this project, for useful insights and not least, for all the support you gave with the statistics.

Ewa Wallin, my friend, fellow PhD student and co-worker, thanks for “daily chats”, joyful times together, discussions and help. For collaboration and for being my support during both research and life in general. I am grateful for our time together.

Marie Sellert Rydberg, co-worker at the Intensive Care Unit, Falun, for your valuable help with inclusion of patients and data collection.

Henrik Zetterberg, co-author, for your expertise and insightful revision of our work, enthusiastic response to my questions and for sharing a part of the world of biomarkers.

Erik Mörtberg, Johanna Nordmark, David Smekal and Erik Lindgren for cooperation throughout the different projects.

Elisabeth Pettersson, for all your help with logistics and to finding things on the 3rd floor.
Joakim Engström, my colleague, fellow PhD student and roommate, for sharing an interest in research, discussions and for your invaluable Apple support.

Marie Thorén, head nurse at the Intensive Care Unit, Uppsala University Hospital, for your support, for creating conditions for research and for allowing me time off from clinical work.

Åsa Fredriksson for all your help with economic issues and changes in the schedule, always with a positive attitude.

Many thanks to all of my colleagues at CIVA throughout the years, for all your help and support with filling out protocols and obtaining blood samples. You are the best colleagues ever.

Katja Andersson for all your assistance. Thank you!

Johann Valtysson, Göran Angergård and Torbjörn Karlsson, former and present heads of the Department of Anaesthesiology and Intensive Care, for providing me with research time.

The PhD-student network for Registered Nurses at Uppsala University Hospital for shared research interest, discussions, valuable support and encouragement.

To Karin Norén, Ann-Sofi Yngveson, Elisabeth Jonasson and Ewa Wallin in the “Literature circle”, for all the years of sharing all kinds of books, conversations and pleasant moments.

Ingegerd and Rolf Larsson, mina föräldrar, för kärlek, stöd och att ni trott på mig.

Anders, my brother, for sharing all memories from our childhood, and his family Carina and Olivia.

And last but not least, my closest family: Mikke, thank you for reading, giving constructive comments and supporting me in my scientific work. But most, for sharing my life. Hugo and Elsa, lastly but most importantly, for being who you are and for giving me an every-day joy. Big love!
References


70


97. Engel H, Ben Hamouda N, Portmann K, et al. Serum procalcitonin as a marker of post-cardiac arrest syndrome and long-term neurological recovery, but not of


160. Rabin R OM, Ope M. EQ-5D-3L User Guide; Basic information on how to use the EQ-5D-3L instrumentVersion 4.0: (2011).


203.
Acta Universitatis Upsaliensis

Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1021

Editor: The Dean of the Faculty of Medicine

A doctoral dissertation from the Faculty of Medicine, Uppsala University, is usually a summary of a number of papers. A few copies of the complete dissertation are kept at major Swedish research libraries, while the summary alone is distributed internationally through the series Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine. (Prior to January, 2005, the series was published under the title “Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine”.)